


**CUMULATIVE
SUPPLEMENT 4**
April 2011



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Cumulative Supplement 4

April 2011

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

**CUMULATIVE SUPPLEMENT 4
April 2011**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically

equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHEROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper

versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2010</u>	<u>MAR 2011</u>	<u>JUN 2011</u>	<u>SEPT 2011</u>	<u>DEC 2011</u>
DRUG PRODUCTS LISTED	13838	14029			
SINGLE SOURCE	2482	2477			
	(17.9%)	(17.7%)			
MULTISOURCE	11267	11463			
	(81.4%)	(81.7%)			
THERAPEUTICALLY	11107	11301			
EQUIVALENT	(80.3%)	(80.6%)			
NOT THERAPEUTICALLY	160	162			
EQUIVALENT	(1.2%)	(1.2%)			
EXCEPTIONS ¹	89	89			
	(0.6%)	(0.6%)			
NEW MOLECULAR ENTITIES					
APPROVED	8	6			
NUMBER OF APPLICANTS	752	768			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 31ST EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

1-1

>A>	<u>ABIRATERONE ACETATE</u>						
>A>	TABLET; ORAL						
>A>	ZYTIGA						
>A>	+	CENTOCOR ORTHO	250MG	N202379	001	Apr 28, 2011	Apr NEWA
	<u>ACETAMINOPHEN; BUTALBITAL; CAFFEINE</u>						
	TABLET; ORAL						
	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
AA	MIRROR PHARMS	325MG;50MG;40MG		A040864	001	Dec 01, 2008	Mar CAHN
AA		500MG;50MG;40MG		A040883	001	Dec 23, 2008	Mar CAHN
	<u>ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE</u>						
	CAPSULE; ORAL						
	ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE						
AA	WRASER PHARMS LLC	356.4MG;30MG;16MG		A040688	001	Apr 03, 2007	Jan CAHN
	<u>ACETAMINOPHEN; HYDROCODONE BITARTRATE</u>						
	TABLET; ORAL						
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	BOCA PHARMA	300MG;5MG		A090415	001	Jan 24, 2011	Feb CTEC
AB		300MG;5MG		A090415	001	Jan 24, 2011	Jan NEWA
AA		300MG;7.5MG		A090415	002	Jan 24, 2011	Feb CTEC
AB		300MG;7.5MG		A090415	002	Jan 24, 2011	Jan NEWA
AA		300MG;10MG		A090415	003	Jan 24, 2011	Feb CTEC
AB		300MG;10MG		A090415	003	Jan 24, 2011	Jan NEWA
AA	+	MIKART	300MG;5MG	A040658	001	Jan 19, 2006	Mar CRLD
AA		300MG;5MG		A040658	001	Jan 19, 2006	Feb CTEC
AA	+	300MG;7.5MG		A040556	002	Mar 24, 2006	Feb CTEC
AA	+	300MG;10MG		A040556	001	Jun 23, 2004	Feb CTEC
	LORTAB						
AA	UCB INC	500MG;5MG		A087722	001	Jul 09, 1982	Jan CAHN
	<u>ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE</u>						
	TABLET; ORAL						
	PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN						
	@	VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003	Mar DISC
	<u>ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE</u>						
	TABLET; ORAL						
	DARVOCET-N 100						
	@	XANODYNE PHARM	650MG;100MG	N017122	002		Jan DISC
	DARVOCET-N 50						
	@	XANODYNE PHARM	325MG;50MG	N017122	001		Jan DISC
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN						
	@	CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004	Mar DISC
	@		500MG;100MG	A076750	001	Jun 28, 2004	Mar DISC
>D>	AB	MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008	Apr DISC
>A>	@		650MG;100MG	A077821	001	Feb 11, 2008	Apr DISC
	AB		650MG;100MG	A077821	001	Feb 11, 2008	Mar CAHN
	@	TEVA	650MG;100MG	A074119	001	Dec 19, 1994	Mar DISC
	@	VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001	Mar DISC
	@		650MG;100MG	A074843	001	Feb 12, 1997	Mar DISC

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB	MYLAN	200MG	A074977 001	Apr 13, 1998	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

AB	MYLAN	400MG	A074976 001	Apr 13, 1998	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

AB		800MG	A074976 002	Apr 13, 1998	Feb	CAHN
----	--	-------	-------------	--------------	-----	------

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

@ HOSPIRA

EQ 50MG BASE/ML

A075065 001	Feb 25, 1999	Feb	DISC
-------------	--------------	-----	------

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL

ACLOVATE

AB	+ NYCOMED US	0.05%	N018702 001	Dec 14, 1982	Mar	CAHN
----	--------------	-------	-------------	--------------	-----	------

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB	MYLAN	EQ 35MG BASE	A078638 001	Aug 04, 2008	Feb	CAHN
----	-------	--------------	-------------	--------------	-----	------

AB		EQ 70MG BASE	A078638 002	Aug 04, 2008	Feb	CAHN
----	--	--------------	-------------	--------------	-----	------

@ SANDOZ	EQ 5MG BASE	A075871 001	Apr 22, 2009	Mar	DISC
----------	-------------	-------------	--------------	-----	------

@	EQ 10MG BASE	A075871 002	Apr 22, 2009	Mar	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 35MG BASE	A075871 004	Apr 22, 2009	Mar	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 40MG BASE	A075871 003	Apr 22, 2009	Mar	DISC
---	--------------	-------------	--------------	-----	------

@	EQ 70MG BASE	A075871 005	Apr 22, 2009	Mar	DISC
---	--------------	-------------	--------------	-----	------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB	IPCA LABS LTD	100MG	A090637 001	Mar 16, 2011	Feb	NEWA
----	---------------	-------	-------------	--------------	-----	------

AB		300MG	A090637 002	Mar 16, 2011	Feb	NEWA
----	--	-------	-------------	--------------	-----	------

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552 001	Apr 08, 2009	Apr	CAHN
-----	----	-----------------	---------------	-------------	--------------	-----	------

>A>	AB		EQ 5MG BASE	A078552 002	Apr 08, 2009	Apr	CAHN
-----	----	--	-------------	-------------	--------------	-----	------

>A>	AB		EQ 10MG BASE	A078552 003	Apr 08, 2009	Apr	CAHN
-----	----	--	--------------	-------------	--------------	-----	------

>D>	AB	GLENMARK GENERICS	EQ 2.5MG BASE	A078552 001	Apr 08, 2009	Apr	CAHN
-----	----	-------------------	---------------	-------------	--------------	-----	------

>D>	AB		EQ 5MG BASE	A078552 002	Apr 08, 2009	Apr	CAHN
-----	----	--	-------------	-------------	--------------	-----	------

>D>	AB		EQ 10MG BASE	A078552 003	Apr 08, 2009	Apr	CAHN
-----	----	--	--------------	-------------	--------------	-----	------

	AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771 001	Apr 12, 2011	Mar	NEWA
--	----	--------------	---------------	-------------	--------------	-----	------

	AB		EQ 5MG BASE	A077771 002	Apr 12, 2011	Mar	NEWA
--	----	--	-------------	-------------	--------------	-----	------

	AB		EQ 10MG BASE	A077771 003	Apr 12, 2011	Mar	NEWA
--	----	--	--------------	-------------	--------------	-----	------

>A>	AB	SECAN PHARMS	EQ 5MG BASE	A090752 001	Apr 15, 2011	Apr	NEWA
-----	----	--------------	-------------	-------------	--------------	-----	------

>A>	AB		EQ 10MG BASE	A090752 002	Apr 15, 2011	Apr	NEWA
-----	----	--	--------------	-------------	--------------	-----	------

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

AB	NOVARTIS	EQ 5MG BASE;40MG	N020364 007	Apr 11, 2006	Jan	CFTG
----	----------	------------------	-------------	--------------	-----	------

CAPSULE; ORAL

LOTREL

AB	+	NOVARTIS	EQ 10MG BASE;40MG	N020364 006	Apr 11, 2006	Jan	CFTG
----	---	----------	-------------------	-------------	--------------	-----	------

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB		AM ANTIBIOTICS	250MG	A062058 001		Feb	CDFR
AB			500MG	A062058 002		Feb	CDFR

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+		DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824 001	Feb 08, 2011	Feb	NEWA
---	--	-----------------	--	-------------	--------------	-----	------

>A> AMPICILLIN SODIUM; SULBACTAM SODIUM

>A> INJECTABLE; INJECTION

>A> AMPICILLIN AND SULBACTAM

>A>	AP	AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349 001	Sep 20, 2010	Apr	CAIN
>A>	AP		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340 001	Sep 20, 2010	Apr	CAIN
>A>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340 002	Sep 20, 2010	Apr	CAIN
>A>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349 002	Sep 20, 2010	Apr	CAIN
>A>	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339 001	Sep 20, 2010	Apr	CAIN

>D> AMPICILLIN; SULBACTAM

>D> INJECTABLE; INJECTION

>D> AMPICILLIN AND SULBACTAM

>D>	AP	AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349 001	Sep 20, 2010	Apr	CAIN
>D>	AP		EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340 001	Sep 20, 2010	Apr	CAIN
>D>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340 002	Sep 20, 2010	Apr	CAIN
>D>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349 002	Sep 20, 2010	Apr	CAIN
>D>	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339 001	Sep 20, 2010	Apr	CAIN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB		SANTOS BIOTECH	1MG	A078944 001	Jun 28, 2010	Feb	CAHN
----	--	----------------	-----	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB		MIRROR PHARMS	325MG;200MG	A040832 001	Jan 07, 2010	Mar	CAHN
AB		PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		MIRROR PHARMS	325MG;200MG;16MG	A040860 001	Jan 07, 2010	Mar	CAHN
AB		PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA	COASTAL PHARMS	325MG;4.8355MG	A091670 001	Mar 16, 2011	Feb	NEWA
AA	WATSON LABS	325MG;4.8355MG	A090084 001	Mar 22, 2011	Mar	NEWA
PERCODAN						
AA	+ ENDO PHARMS	325MG;4.8355MG	N007337 007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	MYLAN	25MG	A074126 003	Aug 26, 1998	Feb	CAHN
AB		50MG	A074126 001	Mar 23, 1994	Feb	CAHN
AB		100MG	A074126 002	Mar 23, 1994	Feb	CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	250MG;100MG	A091211 001	Jan 12, 2011	Jan	NEWA
MALARONE						
AB	+ GLAXOSMITHKLINE	250MG;100MG	N021078 001	Jul 14, 2000	Jan	CFTG

AZILSARTAN MEDOXOMIL

TABLET; ORAL

EDARBI

	TAKEDA PHARMS	40MG	N200796 001	Feb 25, 2011	Feb	NEWA
+		80MG	N200796 002	Feb 25, 2011	Feb	NEWA

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

AP	BEDFORD	1GM/VIAL	A065286 001	Mar 23, 2011	Mar	NEWA
AP		2GM/VIAL	A065286 002	Mar 23, 2011	Mar	NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

+	FERA PHARMS	500 UNITS/GM	A061212 001		Feb	CAHN
+	NYCOMED US	500 UNITS/GM	A061212 001		Jan	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764 002		Feb	CAHN
AT	NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764 002		Jan	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Feb	CAHN
AT	NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002		Feb	CAHN
+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002		Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP	CNS THERAPS INC	0.05MG/ML	N022462 001	Nov 19, 2010	Feb	CTEC
AP		0.5MG/ML	N022462 002	Nov 19, 2010	Feb	CTEC
AP		2MG/ML	N022462 003	Nov 19, 2010	Feb	CTEC

LIORESAL

AP	+	MEDTRONIC	0.05MG/ML	N020075 003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075 001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075 002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	5MG;6.25MG	A076612 001	Feb 11, 2004	Feb	CAHN
AB		10MG;12.5MG	A076612 002	Feb 11, 2004	Feb	CAHN
AB		20MG;12.5MG	A076612 003	Feb 11, 2004	Feb	CAHN
AB		20MG;25MG	A076612 004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP	LUITPOLD	1MG/ML	A091152 001	Mar 29, 2010	Feb	CAHN
----	----------	--------	-------------	--------------	-----	------

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

>D>	AB	STAT TRADE	EQ 0.1% BASE	A070052 001	Jul 31, 1985	Apr	CAHN
>A>	AB	STI PHARMA LLC	EQ 0.1% BASE	A070052 001	Jul 31, 1985	Apr	CAHN

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	ROXANE	50MG	A078285 001	Mar 24, 2011	Mar	NEWA
----	--------	------	-------------	--------------	-----	------

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

	+	ISTA PHARMS INC	0.09%	N021664 002	Oct 16, 2010	Mar	CRLD
>A>		BROMFENAC SODIUM					
>A>		COASTAL PHARMS	0.09%	A201211 001	May 11, 2011	Apr	NEWA
		XIBROM					
		@ ISTA PHARMS INC	0.09%	N021664 001	Mar 24, 2005	Mar	DISC

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	G AND W LABS INC	0.005%	A078468 001	Mar 24, 2011	Mar	NEWA
----	------------------	--------	-------------	--------------	-----	------

CALCIUM ACETATE

>A> SOLUTION; ORAL

>A> PHOSLYRA

>A>	+ FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N022581 001	Apr 18, 2011	Apr	NEWA
-----	-------------------	----------------------	-------------	--------------	-----	------

TABLET; ORAL

CALCIUM ACETATE

AB	PADDOCK LABS	EQ 169MG CALCIUM	A091561 001	Apr 13, 2011	Mar	NEWA
----	--------------	------------------	-------------	--------------	-----	------

ELIPHOS

AB	+ CYPRESS PHARM	EQ 169MG CALCIUM	A078502 001	Nov 25, 2008	Mar	CTEC
----	-----------------	------------------	-------------	--------------	-----	------

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

@ JUBILANT CADISTA	100MG	A071940 001	Feb 01, 1988	Jan	CAHN
--------------------	-------	-------------	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

AB	MERCK SHARP DOHME	10MG;100MG	N017555 001		Jan	CAHN
----	-------------------	------------	-------------	--	-----	------

AB		25MG;100MG	N017555 003		Jan	CAHN
----	--	------------	-------------	--	-----	------

AB	+	25MG;250MG	N017555 002		Jan	CAHN
----	---	------------	-------------	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

AB	MERCK SHARP DOHME	25MG;100MG	N019856 002	Dec 24, 1992	Jan	CAHN
----	-------------------	------------	-------------	--------------	-----	------

AB	+	50MG;200MG	N019856 001	May 30, 1991	Jan	CAHN
----	---	------------	-------------	--------------	-----	------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	MIRROR PHARMS	350MG	A040823 001	Oct 22, 2008	Mar	CAHN
----	---------------	-------	-------------	--------------	-----	------

AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN
----	-------------	-------	-------------	--------------	-----	------

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005	Jan	CAHN
----	-------------	--------------------	-------------	--------------	-----	------

AP		EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005	Jan	CAHN
----	--	------------------	-------------	--------------	-----	------

AP		EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005	Jan	CAHN
----	--	------------------	-------------	--------------	-----	------

AP		EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005	Jan	CAHN
----	--	-------------------	-------------	--------------	-----	------

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065369 001	Jun 18, 2007	Jan	CAHN
----	-------------	--------------------	-------------	--------------	-----	------

AP		EQ 1GM BASE/VIAL	A065369 002	Jun 18, 2007	Jan	CAHN
----	--	------------------	-------------	--------------	-----	------

AP		EQ 2GM BASE/VIAL	A065369 003	Jun 18, 2007	Jan	CAHN
----	--	------------------	-------------	--------------	-----	------

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065290 001	Aug 11, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065293 001	Aug 10, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065290 002	Aug 11, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065290 003	Aug 11, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065293 002	Aug 10, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065292 001	Aug 10, 2006	Jan	CAHN

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313 001	Jan 23, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065313 002	Jan 23, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065312 001	Feb 13, 2006	Jan	CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	+ SANDOZ	EQ 200MG BASE	A065462 002	May 28, 2008	Jan	CRLD
	VANTIN					
	@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674 001	Aug 07, 1992	Jan	DISC
	@	EQ 200MG BASE	N050674 002	Aug 07, 1992	Jan	DISC

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230 001	Aug 02, 2005	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A065230 002	Aug 02, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065230 003	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065230 004	Aug 02, 2005	Jan	CAHN

INJECTABLE; INJECTION

CEFTRIAZONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231 001	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065231 002	Aug 02, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065232 001	Aug 02, 2005	Jan	CAHN
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A065168 001	May 17, 2005	Jan	CRLD

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048 001	Jan 09, 2004	Mar	CTEC
AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483 001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTION

CEFUROXIME SODIUM

AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483 002	Oct 15, 2008	Jan	CAHN
AP		EQ 1.5GM BASE/VIAL	A065503 001	Oct 15, 2008	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A065484 001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

	@ ACS DOBFAR	EQ 100MG BASE/ML	A062117 001		Jan	CAHN
AB		EQ 125MG BASE/5ML	A062117 002		Jan	CAHN

FOR SUSPENSION; ORAL

CEPHALEXIN

AB	+	ACS DOBFAR	EQ 250MG BASE/5ML	A062117 003		Jan	CAHN
----	---	------------	-------------------	-------------	--	-----	------

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT		LYNE	0.12%	A074291 001	Dec 28, 1995	Feb	CAHN
----	--	------	-------	-------------	--------------	-----	------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA		NATCO PHARMA LTD	EQ 150MG BASE	A091621 001	Jan 21, 2011	Jan	NEWA
AA			EQ 300MG BASE	A090612 001	Jan 21, 2011	Jan	NEWA

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

>D>	AB		SANDOZ	EQ 4GM RESIN/PACKET	A074557 001	Aug 15, 1996	Apr	CRLD
>A>	AB	+		EQ 4GM RESIN/PACKET	A074557 001	Aug 15, 1996	Apr	CRLD
			CHOLESTYRAMINE LIGHT					
>D>	AB		SANDOZ	EQ 4GM RESIN/PACKET	A074558 001	Aug 15, 1996	Apr	CRLD
>A>	AB	+		EQ 4GM RESIN/PACKET	A074558 001	Aug 15, 1996	Apr	CRLD
			QUESTRAN					
>D>	AB	+	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N016640 001		Apr	DISC
>D>	AB			EQ 4GM RESIN/SCOOPFUL	N016640 003		Apr	DISC
>A>		@		EQ 4GM RESIN/PACKET	N016640 001		Apr	DISC
>A>		@		EQ 4GM RESIN/SCOOPFUL	N016640 003		Apr	DISC
			QUESTRAN LIGHT					
>D>	AB	+	BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Apr	DISC
>D>	AB			EQ 4GM RESIN/SCOOPFUL	N019669 003	Dec 05, 1988	Apr	DISC
>A>		@		EQ 4GM RESIN/SCOOPFUL	N019669 003	Dec 05, 1988	Apr	DISC
>A>		@		EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Apr	DISC
	AB	+		EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Mar	CRLD

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT		TARO	1%	A090269 001	Feb 23, 2011	Feb	NEWA
----	--	------	----	-------------	--------------	-----	------

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>D>	AB		MATRIX LABS INC	EQ 10MG BASE	A077042 001	Nov 05, 2004	Apr	CAHN
>D>	AB			EQ 20MG BASE	A077042 002	Nov 05, 2004	Apr	CAHN
>D>	AB			EQ 40MG BASE	A077042 003	Nov 05, 2004	Apr	CAHN
>A>	AB		MYLAN	EQ 10MG BASE	A077042 001	Nov 05, 2004	Apr	CAHN
>A>	AB			EQ 20MG BASE	A077042 002	Nov 05, 2004	Apr	CAHN
>A>	AB			EQ 40MG BASE	A077042 003	Nov 05, 2004	Apr	CAHN

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAGEL

BT	+	GALDERMA LABS LP	EQ 1% BASE	N050782 001	Nov 27, 2000	Mar	CRLD
----	---	------------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

>A>	@ COREPHARMA	EQ 1% BASE	A064108	001	Sep 27, 1996	Apr	CAHN
>D>	@ STIEFEL GSK	EQ 1% BASE	A064108	001	Sep 27, 1996	Apr	CAHN

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

>A>	@ COREPHARMA	0.05%	A075338	001	Feb 09, 2001	Apr	CAHN
>D>	@ STIEFEL	0.05%	A075338	001	Feb 09, 2001	Apr	CAHN
CLOBETASOL PROPIONATE (EMOLLIENT)							
>A>	@ COREPHARMA	0.05%	A075733	001	Aug 22, 2001	Apr	CAHN
>D>	@ STIEFEL GSK	0.05%	A075733	001	Aug 22, 2001	Apr	CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

>A>	@ COREPHARMA	0.05%	A075057	001	Aug 12, 1998	Apr	CAHN
>D>	@ STIEFEL GSK	0.05%	A075057	001	Aug 12, 1998	Apr	CAHN

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

>D>	AT	ALTANA	0.05%	A075391	001	Feb 08, 1999	Apr	CAHN
>A>	AT	NYCOMED US	0.05%	A075391	001	Feb 08, 1999	Apr	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

AP	WEST WARD	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jan	NEWA
AP		5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jan	NEWA

COLCHICINE; PROBENECID

TABLET; ORAL

PROBENECID AND COLCHICINE

AB	MIRROR PHARMS	0.5MG;500MG	A040618	001	May 13, 2008	Mar	CAHN
----	---------------	-------------	---------	-----	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

>D>	ANESTA AG	15MG	N021777	001	Feb 01, 2007	Apr	CFTG
>A>	AB	15MG	N021777	001	Feb 01, 2007	Apr	CFTG
>D>	+	30MG	N021777	002	Feb 01, 2007	Apr	CFTG
>A>	AB	30MG	N021777	002	Feb 01, 2007	Apr	CFTG

CYCLOBENZAPRINE HYDROCHLORIDE

>A>	AB	MYLAN	15MG	A090738	001	Apr 18, 2011	Apr	NEWA
>A>	AB		30MG	A090738	002	Apr 18, 2011	Apr	NEWA

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	JUBILANT CADISTA	5MG	A077563	001	Apr 19, 2006	Jan	CAHN
AB		10MG	A077563	002	Apr 19, 2006	Jan	CAHN
AB	KVK TECH	5MG	A078048	001	Feb 28, 2011	Feb	NEWA
AB		10MG	A078048	002	Feb 28, 2011	Feb	NEWA
AB	PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
AB		10MG	A077209	001	Oct 04, 2005	Feb	CAHN

DESLOMATADINE

TABLET; ORAL

DESLOMATADINE

AB	DR REDDYS LABS LTD	5MG	A078365	001	Mar 08, 2011	Feb	NEWA
----	--------------------	-----	---------	-----	--------------	-----	------

DES Loratadine; Pseudoephedrine Sulfate

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

>D>	+	SCHERING	5MG;240MG	N021605	001	Mar 03, 2005	Apr	CFTG
>A>	AB	+	5MG;240MG	N021605	001	Mar 03, 2005	Apr	CFTG
>A>		DES Loratadine AND Pseudoephedrine Sulfate 24 HOUR						
>A>	AB	DR REDDYS LABS LTD	5MG;240MG	A078366	001	Apr 26, 2011	Apr	NEWA

Desogestrel; Ethinyl Estradiol

TABLET; ORAL-28

EMOQUETTE

AB	VINTAGE	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Feb	NEWA
----	---------	---------------	---------	-----	--------------	-----	------

Desoximetasone

GEL; TOPICAL

DES OXIMETASONE

AB	VERSAPHARM	0.05%	A090727	001	Mar 10, 2011	Feb	NEWA
----	------------	-------	---------	-----	--------------	-----	------

Dexamethasone

ELIXIR; ORAL

DEXAMETHASONE

>A>	AA	VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011	Apr	NEWA
-----	----	----------------	-----------	---------	-----	--------------	-----	------

Dexamethasone; Neomycin Sulfate; Polymyxin B Sulfate

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Feb	CAHN
AT	NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jan	CAHN

Dextromethorphan Hydrobromide; Promethazine Hydrochloride

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011	Jan	NEWA
----	---------------	---------------------	---------	-----	--------------	-----	------

Diclofenac Sodium

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

>D>	AB	BIOVAIL	100MG	A075492	001	Feb 11, 2000	Apr	CAHN
>A>	AB	VALEANT INTL	100MG	A075492	001	Feb 11, 2000	Apr	CAHN

Diltiazem Hydrochloride

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

>D>	AB3	BIOVAIL	120MG	A075116	001	Dec 23, 1999	Apr	CAHN
>D>	AB3		180MG	A075116	002	Dec 23, 1999	Apr	CAHN
>D>	AB3		240MG	A075116	003	Dec 23, 1999	Apr	CAHN
>D>	AB3		300MG	A075116	004	Dec 23, 1999	Apr	CAHN
>A>	AB3	VALEANT INTL	120MG	A075116	001	Dec 23, 1999	Apr	CAHN
>A>	AB3		180MG	A075116	002	Dec 23, 1999	Apr	CAHN
>A>	AB3		240MG	A075116	003	Dec 23, 1999	Apr	CAHN
>A>	AB3		300MG	A075116	004	Dec 23, 1999	Apr	CAHN

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB		50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB		75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISULFIRAM

TABLET; ORAL

ANTABUSE

AB	ODYSSEY PHARMS	250MG	A088482 001	Dec 08, 1983	Mar	CTEC
AB	+	500MG	A088483 001	Dec 08, 1983	Mar	CTEC

DISULFIRAM

AB	SIGMAPHARM LABS LLC	250MG	A091619 001	Mar 28, 2011	Mar	NEWA
AB		500MG	A091619 002	Mar 28, 2011	Mar	NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DIVALPROEX SODIUM

AB	MYLAN	EQ 125MG VALPROIC ACID	A090407 001	Mar 28, 2011	Mar	NEWA
----	-------	------------------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

>A>	AB	AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554 001	Apr 21, 2011	Apr	NEWA
>A>	AB		EQ 250MG VALPROIC ACID	A090554 002	Apr 21, 2011	Apr	NEWA
>A>	AB		EQ 500MG VALPROIC ACID	A090554 003	Apr 21, 2011	Apr	NEWA
	AB	UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163 001	Apr 05, 2011	Mar	NEWA
	AB		EQ 250MG VALPROIC ACID	A079163 002	Apr 05, 2011	Mar	NEWA
	AB		EQ 500MG VALPROIC ACID	A079163 003	Apr 05, 2011	Mar	NEWA
	AB	WATSON LABS FLORIDA	EQ 500MG VALPROIC ACID	A079080 001	Feb 25, 2011	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234 001	Mar 08, 2011	Mar	NEWA
+		80MG/8ML (10MG/ML)	N022234 002	Mar 08, 2011	Mar	NEWA
+		160MG/16ML (10MG/ML)	N022234 003	Mar 08, 2011	Mar	NEWA

TAXOTERE

@	SANOFI AVENTIS US	40MG/ML	N020449 001	May 14, 1996	Mar	DISC
---	-------------------	---------	-------------	--------------	-----	------

DONEPEZIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	SANDOZ	5MG	A091198 001	May 10, 2011	Apr	NEWA
>A>	AB		10MG	A091198 002	May 10, 2011	Apr	NEWA
>A>	AB	ZYDUS PHARMS USA INC	5MG	A090175 001	May 10, 2011	Apr	NEWA
>A>	AB		10MG	A090175 002	May 10, 2011	Apr	NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	IMPAX LABS INC	EQ 150MG BASE	A200065 001	Feb 17, 2011	Jan	NEWA	
AB	MYLAN	40MG	A090855 001	Jul 01, 2010	Jan	CDFR	
AB	+	PAR PHARM	EQ 150MG BASE	A065055 003	Jul 15, 2005	Feb	CTEC
AB	+		EQ 150MG BASE	A065055 003	Jul 15, 2005	Jan	CTEC

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

LORYNA

AB		SANDOZ	3MG;0.02MG	A079221	001	Mar 28, 2011	Mar	NEWA
----	--	--------	------------	---------	-----	--------------	-----	------

TABLET; ORAL-28

SYEDA

AB		SANDOZ	3MG;0.03MG	A090114	001	Mar 28, 2011	Mar	NEWA
----	--	--------	------------	---------	-----	--------------	-----	------

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

LOVENOX

		SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003	Feb	CDFR
--	--	-------------------	----------------------	---------	-----	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT	+	ALLERGAN	0.05%	N021565	001	Oct 16, 2003	Feb	CFTG
----	---	----------	-------	---------	-----	--------------	-----	------

EPINASTINE HYDROCHLORIDE

AT		CYPRESS PHARM	0.05%	A090870	001	Mar 14, 2011	Feb	NEWA
----	--	---------------	-------	---------	-----	--------------	-----	------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

>A>	AP	MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Apr	NEWA
-----	----	----------------	--------------------	---------	-----	--------------	-----	------

>A>	AP		200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Apr	NEWA
-----	----	--	----------------------	---------	-----	--------------	-----	------

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYTHROMYCIN

AB		ARBOR PHARMS INC	250MG	A062746	001	Dec 22, 1986	Jan	CAHN
----	--	------------------	-------	---------	-----	--------------	-----	------

GEL; TOPICAL

E-GLADES

>A>	AT	COREPHARMA	2%	A065009	001	Mar 18, 2002	Apr	CAHN
-----	----	------------	----	---------	-----	--------------	-----	------

>D>	AT	STIEFEL LABS INC	2%	A065009	001	Mar 18, 2002	Apr	CAHN
-----	----	------------------	----	---------	-----	--------------	-----	------

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT	+	FERA PHARMS	0.5%	A062447	001	Sep 26, 1983	Feb	CAHN
----	---	-------------	------	---------	-----	--------------	-----	------

AT	+	NYCOMED US	0.5%	A062447	001	Sep 26, 1983	Jan	CAHN
----	---	------------	------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

ERYDERM

		@ ARBOR PHARMS INC	2%	A062290	001		Jan	CAHN
--	--	--------------------	----	---------	-----	--	-----	------

ERYTHROMYCIN

>A>		@ COREPHARMA	2%	A064127	001	Feb 14, 1997	Apr	CAHN
-----	--	--------------	----	---------	-----	--------------	-----	------

>D>		@ STIEFEL	2%	A064127	001	Feb 14, 1997	Apr	CAHN
-----	--	-----------	----	---------	-----	--------------	-----	------

SWAB; TOPICAL

ERYTHROMYCIN

>A>		@ COREPHARMA	2%	A064128	001	Jul 03, 1996	Apr	CAHN
-----	--	--------------	----	---------	-----	--------------	-----	------

>D>		@ STIEFEL	2%	A064128	001	Jul 03, 1996	Apr	CAHN
-----	--	-----------	----	---------	-----	--------------	-----	------

TABLET; ORAL

ERYTHROMYCIN

		ARBOR PHARMS INC	250MG	A061621	001		Jan	CAHN
--	--	------------------	-------	---------	-----	--	-----	------

+ 500MG

A061621	002		Jan	CAHN
---------	-----	--	-----	------

TABLET, COATED PARTICLES; ORAL

PCE

		ARBOR PHARMS INC	333MG	N050611	001	Sep 09, 1986	Jan	CAHN
--	--	------------------	-------	---------	-----	--------------	-----	------

TABLET, COATED PARTICLES; ORAL

PCE

+	ARBOR PHARMS INC	500MG	N050611 002	Aug 22, 1990	Jan	CAHN
---	------------------	-------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

E-MYCIN

@	ARBOR PHARMS INC	250MG	A060272 001		Jan	CAHN
---	------------------	-------	-------------	--	-----	------

@		333MG	A060272 002		Jan	CAHN
---	--	-------	-------------	--	-----	------

ERY-TAB

+	ARBOR PHARMS INC	250MG	A062298 001		Jan	CAHN
---	------------------	-------	-------------	--	-----	------

+		333MG	A062298 003	Mar 29, 1982	Jan	CAHN
---	--	-------	-------------	--------------	-----	------

+		500MG	A062298 002		Jan	CAHN
---	--	-------	-------------	--	-----	------

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207 001		Jan	CAHN
----	------------------	-------------------	-------------	--	-----	------

ERYPED

AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207 003	Mar 30, 1987	Jan	CAHN
----	------------------	-------------------	-------------	--------------	-----	------

+		EQ 400MG BASE/5ML	N050207 002		Jan	CAHN
---	--	-------------------	-------------	--	-----	------

SUSPENSION; ORAL

E.E.S. 200

AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A061639 001		Jan	CAHN
----	------------------	-------------------	-------------	--	-----	------

E.E.S. 400

AB	+	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A061639 002		Jan	CAHN
----	---	------------------	-------------------	-------------	--	-----	------

PEDIAMYCIN

AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A062304 001		Jan	CAHN
----	------------------	-------------------	-------------	--	-----	------

PEDIAMYCIN 400

AB	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A062304 002		Jan	CAHN
----	------------------	-------------------	-------------	--	-----	------

TABLET; ORAL

E.E.S. 400

@	ARBOR PHARMS INC	EQ 400MG BASE	A061905 001		Jan	CAHN
---	------------------	---------------	-------------	--	-----	------

BX	+		EQ 400MG BASE	A061905 002	Aug 12, 1982	Jan	CAHN
----	---	--	---------------	-------------	--------------	-----	------

ERYTHROMYCIN ETHYLSUCCINATE

BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A061904 001		Jan	CAHN
----	---	------------------	---------------	-------------	--	-----	------

TABLET, CHEWABLE; ORAL

E.E.S.

@	ARBOR PHARMS INC	EQ 200MG BASE	N050297 002		Jan	CAHN
---	------------------	---------------	-------------	--	-----	------

ERYPED

@	ARBOR PHARMS INC	EQ 200MG BASE	N050297 003	Jul 05, 1988	Jan	CAHN
---	------------------	---------------	-------------	--------------	-----	------

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

@	ARBOR PHARMS INC	EQ 125MG BASE	A060359 002		Jan	CAHN
---	------------------	---------------	-------------	--	-----	------

		EQ 250MG BASE	A060359 001		Jan	CAHN
--	--	---------------	-------------	--	-----	------

+		EQ 500MG BASE	A060359 003		Jan	CAHN
---	--	---------------	-------------	--	-----	------

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

AB	NOVO NORDISK INC	0.5MG;0.1MG	N020907 002	Dec 28, 2006	Mar	CTEC
----	------------------	-------------	-------------	--------------	-----	------

ESTRADIOL AND NORETHINDRONE ACETATE

AB	BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324 002	Apr 04, 2011	Mar	NEWA
----	--------------------	-------------	-------------	--------------	-----	------

ESTROPIPATE

>D>	CREAM; VAGINAL					
>D>	OGEN					
>D>	+ PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001	Apr	DISC
>A>	@	1.5MG/GM	A084710	001	Apr	DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

	TABLET; ORAL-28					
>A>	ORSYTHIA					
>A>	AB1 VINTAGE PHARMS	0.02MG;0.1MG	A077099	001	May 11, 2011	Apr NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET; ORAL-28					
	BRIELLYN					
AB	GLENMARK GENERICS	0.035MG;0.4MG	A090538	001	Mar 22, 2011	Mar NEWA
	TABLET, CHEWABLE; ORAL					
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	+ WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET; ORAL-28					
	GILDESS FE 1.5/30					
AB	VINTAGE	0.03MG;1.5MG	A077075	001	Apr 28, 2005	Jan CTNA
	GILDESS FE 1/20					
AB	VINTAGE	0.02MG;1MG	A077077	001	May 20, 2005	Jan CTNA

ETHINYL ESTRADIOL; NORGESTIMATE

	TABLET; ORAL-28					
	NORGESTIMATE AND ETHINYL ESTRADIOL					
AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011	Feb NEWA

ETODOLAC

	CAPSULE; ORAL					
	ETODOLAC					
	@ MYLAN	200MG	A075071	001	Sep 30, 1998	Feb CAHN
	@	300MG	A075071	002	Sep 30, 1998	Feb CAHN
	TABLET; ORAL					
	ETODOLAC					
	@ MYLAN	400MG	A075012	001	Sep 30, 1998	Feb CAHN
	@	500MG	A075012	002	Sep 30, 1998	Feb CAHN

ETRAVIRINE

	TABLET; ORAL					
	INTELENCE					
	TIBOTEC	100MG	N022187	001	Jan 18, 2008	Jan CRLD
	+	200MG	N022187	002	Dec 22, 2010	Jan NEWA

EXEMESTANE

	TABLET; ORAL					
	AROMASIN					
AB	+ PHARMACIA AND UPJOHN	25MG	N020753	001	Oct 21, 1999	Mar CFTG
	EXEMESTANE					
AB	ROXANE	25MG	A077431	001	Apr 01, 2011	Mar NEWA

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	AUROBINDO PHARMA LTD	125MG	A091114 001	Mar 21, 2011	Mar	NEWA
AB		250MG	A091114 002	Mar 21, 2011	Mar	NEWA
AB		500MG	A091114 003	Mar 21, 2011	Mar	NEWA
AB	MYLAN	125MG	A201333 001	Mar 24, 2011	Mar	NEWA
AB		250MG	A201333 002	Mar 24, 2011	Mar	NEWA
AB		500MG	A201333 003	Mar 24, 2011	Mar	NEWA
AB	ROXANE	125MG	A090128 001	Mar 21, 2011	Mar	NEWA
AB		250MG	A090128 002	Mar 21, 2011	Mar	NEWA
AB		500MG	A090128 003	Mar 21, 2011	Mar	NEWA
AB	WATSON LABS	125MG	A078278 001	Mar 21, 2011	Mar	NEWA
AB		250MG	A078278 002	Mar 21, 2011	Mar	NEWA
AB		500MG	A078278 003	Mar 21, 2011	Mar	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

PEPCID

@ MERCK	10MG/ML	N019510 001	Nov 04, 1986	Jan	DISC
---------	---------	-------------	--------------	-----	------

PEPCID PRESERVATIVE FREE

@ MERCK	10MG/ML	N019510 004	Nov 04, 1986	Jan	DISC
---------	---------	-------------	--------------	-----	------

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

@ MERCK	0.4MG/ML	N020249 001	Feb 18, 1994	Jan	DISC
---------	----------	-------------	--------------	-----	------

TABLET; ORAL

FAMOTIDINE

AB	MYLAN	20MG	A075457 001	Apr 18, 2001	Feb	CAHN
AB		40MG	A075457 002	Apr 18, 2001	Feb	CAHN

FAMOTIDINE; IBUPROFEN

>A>	TABLET; ORAL					
>A>	DUEXIS					
>A>	+ HORIZON PHARMA	26.6MG;800MG	N022519 001	Apr 23, 2011	Apr	NEWA

FENOFIBRATE

TABLET; ORAL

FENOGLIDE

SHORE THERAP	40MG	N022118 001	Aug 10, 2007	Feb	CAHN
+	120MG	N022118 002	Aug 10, 2007	Feb	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB	MALLINCKRODT INC	100MCG/HR	A077154 004	Feb 09, 2011	Jan	NEWA
	FENTANYL-25					
AB	MALLINCKRODT INC	25MCG/HR	A077154 001	Feb 09, 2011	Jan	NEWA
	FENTANYL-50					
AB	MALLINCKRODT INC	50MCG/HR	A077154 002	Feb 09, 2011	Jan	NEWA
	FENTANYL-75					
AB	MALLINCKRODT INC	75MCG/HR	A077154 003	Feb 09, 2011	Jan	NEWA

FENTANYL CITRATE

TABLET; SUBLINGUAL

ABSTRAL

PROSTRAKAN INC	EQ 0.1MG BASE	N022510 001	Jan 07, 2011	Jan	NEWA
----------------	---------------	-------------	--------------	-----	------

TABLET; SUBLINGUAL

ABSTRAL

	PROSTRAKAN INC	EQ 0.2MG BASE	N022510 002	Jan 07, 2011	Jan	NEWA
		EQ 0.3MG BASE	N022510 003	Jan 07, 2011	Jan	NEWA
+		EQ 0.4MG BASE	N022510 004	Jan 07, 2011	Jan	NEWA
		EQ 0.6MG BASE	N022510 005	Jan 07, 2011	Jan	NEWA
		EQ 0.8MG BASE	N022510 006	Jan 07, 2011	Jan	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS LABS LTD	180MG;240MG	A079043 001	Mar 17, 2010	Jan	CTEC
--	--------------------	-------------	-------------	--------------	-----	------

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB	AMNEAL PHARM	50MG	A078423 001	Mar 07, 2011	Feb	NEWA
AB		100MG	A078423 002	Mar 07, 2011	Feb	NEWA
AB		150MG	A078423 003	Mar 07, 2011	Feb	NEWA
AB		200MG	A078423 004	Mar 07, 2011	Feb	NEWA
AB	MYLAN	50MG	A076042 001	Jul 29, 2004	Feb	CAHN
AB		100MG	A076042 002	Jul 29, 2004	Feb	CAHN
AB		150MG	A076042 003	Jul 29, 2004	Feb	CAHN
AB		200MG	A076042 004	Jul 29, 2004	Feb	CAHN

FLUDARABINE PHOSPHATE

TABLET; ORAL

OFORTA

>D>	@ SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008	Apr	CMFD
>A>	+	10MG	N022273 001	Dec 18, 2008	Apr	CMFD
	@	10MG	N022273 001	Dec 18, 2008	Jan	DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	+	FEINSTEIN	20-200mCi/ML	N021870 001	Aug 19, 2005	Feb	CTEC
AP		PETNET	20-200mCi/ML	A079086 001	Feb 25, 2011	Feb	NEWA

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

>A>	AP	SANDOZ	2.5GM/50ML (50MG/ML)	A091299 001	May 02, 2011	Apr	NEWA
>A>	AP		5GM/100ML (50MG/ML)	A091299 002	May 02, 2011	Apr	NEWA
		@ VALEANT	500MG/10ML (50MG/ML)	N012209 001		Mar	DISC

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

>D>	AB1	ALEMBIC LTD	EQ 10MG BASE	A090223 001	Mar 19, 2009	Apr	CAHN
>D>	AB1		EQ 20MG BASE	A090223 002	Mar 19, 2009	Apr	CAHN
>D>	AB		EQ 40MG BASE	A090223 003	Mar 19, 2009	Apr	CAHN
>A>	AB1	ALEMBIC PHARMS LTD	EQ 10MG BASE	A090223 001	Mar 19, 2009	Apr	CAHN
>A>	AB1		EQ 20MG BASE	A090223 002	Mar 19, 2009	Apr	CAHN
>A>	AB		EQ 40MG BASE	A090223 003	Mar 19, 2009	Apr	CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	MYLAN	125MG	A076224 001	May 09, 2003	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

LOTION; TOPICAL

CUTIVATE

>D>	+	NYCOMED US	0.05%	N021152 001	Mar 31, 2005	Apr	CFTG
-----	---	------------	-------	-------------	--------------	-----	------

>A>	AB	+	0.05%	N021152 001	Mar 31, 2005	Apr	CFTG
-----	----	---	-------	-------------	--------------	-----	------

>A>		FLUTICASONE PROPIONATE					
-----	--	------------------------	--	--	--	--	--

>A>	AB	GLENMARK GENERICS	0.05%	A090759 001	May 02, 2011	Apr	NEWA
-----	----	-------------------	-------	-------------	--------------	-----	------

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ MYLAN

50MG

A075950 001	Oct 15, 2001	Feb	CAHN
-------------	--------------	-----	------

@

100MG

A075950 002	Oct 15, 2001	Feb	CAHN
-------------	--------------	-----	------

FOLIC ACID

TABLET; ORAL

FOLIC ACID

>A>	AA	+	AMNEAL PHARM	1MG	A040625 001	Jul 21, 2005	Apr	CAHN
-----	----	---	--------------	-----	-------------	--------------	-----	------

	AA		JUBILANT CADISTA	1MG	A040514 001	Jun 14, 2005	Jan	CAHN
--	----	--	------------------	-----	-------------	--------------	-----	------

>D>	AA	+	PHARMAX	1MG	A040625 001	Jul 21, 2005	Apr	CAHN
-----	----	---	---------	-----	-------------	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB	AUROBINDO PHARMA LTD	10MG	A091163 001	Mar 30, 2011	Mar	NEWA
----	----------------------	------	-------------	--------------	-----	------

AB		20MG	A091163 002	Mar 30, 2011	Mar	NEWA
----	--	------	-------------	--------------	-----	------

AB		40MG	A091163 003	Mar 30, 2011	Mar	NEWA
----	--	------	-------------	--------------	-----	------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

>D>	AP		APP PHARMS	EQ 50MG PHENYTOIN NA/ML	A078052 001	Aug 06, 2007	Apr	CRLD
-----	----	--	------------	-------------------------	-------------	--------------	-----	------

>A>	AP	+		EQ 50MG PHENYTOIN NA/ML	A078052 001	Aug 06, 2007	Apr	CRLD
-----	----	---	--	-------------------------	-------------	--------------	-----	------

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	MATRIX LABS LTD	100MG	A090158 001	Feb 14, 2011	Jan	NEWA
----	-----------------	-------	-------------	--------------	-----	------

AB		300MG	A090158 002	Feb 14, 2011	Jan	NEWA
----	--	-------	-------------	--------------	-----	------

AB		400MG	A090158 003	Feb 14, 2011	Jan	NEWA
----	--	-------	-------------	--------------	-----	------

SOLUTION; ORAL

GABAPENTIN

AA	HI TECH PHARMA	250MG/5ML	A078974 001	Feb 18, 2011	Feb	NEWA
----	----------------	-----------	-------------	--------------	-----	------

NEURONTIN

AA	+	PARKE DAVIS	250MG/5ML	N021129 001	Mar 02, 2000	Feb	CFTG
----	---	-------------	-----------	-------------	--------------	-----	------

TABLET; ORAL

GABAPENTIN

AB	ZYDUS PHARMS USA INC	600MG	A078926 001	Feb 11, 2011	Jan	NEWA
----	----------------------	-------	-------------	--------------	-----	------

AB		800MG	A078926 002	Feb 11, 2011	Jan	NEWA
----	--	-------	-------------	--------------	-----	------

TABLET; ORAL

GRALISE

BX	+	ABBOTT PRODS	300MG	N022544 001	Jan 28, 2011	Jan	NEWA
BX	+		600MG	N022544 002	Jan 28, 2011	Jan	NEWA

>A> GABAPENTIN ENACARBIL

>A> TABLET, EXTENDED RELEASE; ORAL

>A> HORIZANT

>A>	+	GLAXO GRP LTD	600MG	N022399 001	Apr 06, 2011	Apr	NEWA
-----	---	---------------	-------	-------------	--------------	-----	------

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

+	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277 001	Mar 14, 2011	Mar	NEWA
+		6.0472GM/10ML (604.72MG/ML)	N201277 002	Mar 14, 2011	Mar	NEWA
+		9.0708GM/15ML (604.72MG/ML)	N201277 003	Mar 14, 2011	Mar	NEWA
+		18.1416GM/30ML (604.72MG/ML)	N201277 004	Mar 14, 2011	Mar	NEWA
+		39.3068GM/65ML (604.72MG/ML)	N201277 005	Mar 14, 2011	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB	MYLAN	EQ 8MG BASE	A090900 001	Jan 24, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090900 002	Jan 24, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090900 003	Jan 24, 2011	Jan	NEWA
AB	SUN PHARMA GLOBAL	EQ 8MG BASE	A090178 001	Feb 02, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090178 002	Feb 02, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090178 003	Feb 02, 2011	Jan	NEWA

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957 001	Mar 29, 2011	Mar	NEWA
AB		EQ 8MG BASE	A090957 002	Mar 29, 2011	Mar	NEWA
AB		EQ 12MG BASE	A090957 003	Mar 29, 2011	Mar	NEWA
AB	ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898 001	Feb 17, 2011	Jan	NEWA
AB		EQ 8MG BASE	A078898 002	Feb 17, 2011	Jan	NEWA
AB		EQ 12MG BASE	A078898 003	Feb 17, 2011	Jan	NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE

+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183 001	Nov 15, 2010	Feb	CRLD
---	-------------	------------------	-------------	--------------	-----	------

GEMCITABINE HYDROCHLORIDE

AP	TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983 002	Jan 25, 2011	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A077983 001	Jan 25, 2011	Jan	NEWA

GEMZAR

AP	+	LILLY	EQ 200MG BASE/VIAL	N020509 001	May 15, 1996	Jan	CFTG
AP	+		EQ 1GM BASE/VIAL	N020509 002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB	BLU CARIBE	600MG	A078012 001	Mar 26, 2007	Feb	CAHN
----	------------	-------	-------------	--------------	-----	------

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	FERA PHARMS	EQ 0.3% BASE	A065024 001	Jul 30, 2004	Feb	CAHN
AT	NYCOMED US	EQ 0.3% BASE	A065024 001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

AT	FERA PHARMS	EQ 0.3% BASE	A065121 001	Jan 30, 2004	Feb	CAHN
----	-------------	--------------	-------------	--------------	-----	------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	MYLAN	1MG	A077486 001	Feb 10, 2006	Feb	CAHN
AB		2MG	A077486 002	Feb 10, 2006	Feb	CAHN
AB		4MG	A077486 003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	2.5MG;250MG	A078905 001	Jan 31, 2011	Jan	NEWA
AB		2.5MG;500MG	A078905 002	Jan 31, 2011	Jan	NEWA
AB		5MG;500MG	A078905 003	Jan 31, 2011	Jan	NEWA

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB	INDICUS PHARMA	1.25MG	A090937 001	Feb 28, 2011	Feb	NEWA
AB		2.5MG	A090937 002	Feb 28, 2011	Feb	NEWA
AB		5MG	A090937 003	Feb 28, 2011	Feb	NEWA

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

@ ELORAC	125MG	A061996 001		Jan	CAHN
@	250MG	A061996 002		Jan	CAHN

FULVICIN P/G 165

@ ELORAC	165MG	A061996 003	Apr 06, 1982	Jan	CAHN
----------	-------	-------------	--------------	-----	------

FULVICIN P/G 330

@ ELORAC	330MG	A061996 004	Apr 06, 1982	Jan	CAHN
----------	-------	-------------	--------------	-----	------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

>A>	AB	NOVEL LABS INC	1.5MG;5MG	A091528 001	Apr 20, 2011	Apr	NEWA
		TUSSIGON					
>D>	+	KING PHARMS	1.5MG;5MG	A088508 001	Jul 30, 1985	Apr	CTEC
>A>	AB	+	1.5MG;5MG	A088508 001	Jul 30, 1985	Apr	CTEC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

>D>	AB	ALEMBIC LTD	12.5MG	A200645 001	Nov 30, 2010	Apr	CAHN
>A>	AB	ALEMBIC PHARMS LTD	12.5MG	A200645 001	Nov 30, 2010	Apr	CAHN
	AB	JUBILANT CADISTA	12.5MG	A078391 001	Feb 11, 2008	Jan	CAHN

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	JUBILANT CADISTA	25MG	A040809 001	Sep 04, 2007	Jan	CAHN
AB		50MG	A040809 002	Sep 04, 2007	Jan	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	12.5MG;50MG	A200180 001	Jan 12, 2011	Jan	NEWA
AB		12.5MG;100MG	A200180 002	Jan 12, 2011	Jan	NEWA
AB		25MG;100MG	A200180 003	Jan 12, 2011	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	AB	INVAGEN PHARMS	12.5MG;10MG	A201356 001	Apr 20, 2011	Apr	NEWA
>A>	AB		12.5MG;20MG	A201356 002	Apr 20, 2011	Apr	NEWA
>A>	AB		25MG;20MG	A201356 003	Apr 20, 2011	Apr	NEWA

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

>A>	AB	COREPHARMA	5MG	A040646 001	Mar 30, 2007	Apr	CAHN
>A>	AB		10MG	A040646 002	Mar 30, 2007	Apr	CAHN
>A>	AB		20MG	A040646 003	Mar 30, 2007	Apr	CAHN
>D>	AB	STIEFEL GSK	5MG	A040646 001	Mar 30, 2007	Apr	CAHN
>D>	AB		10MG	A040646 002	Mar 30, 2007	Apr	CAHN
>D>	AB		20MG	A040646 003	Mar 30, 2007	Apr	CAHN

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

@ FERA PHARMS	0.5%	A080828 001		Mar	CAHN
---------------	------	-------------	--	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	ELITE LABS	8MG	A076723 001	Oct 18, 2005	Feb	CAHN
----	------------	-----	-------------	--------------	-----	------

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

>D>						
>A>	@ MERCK SANTE SAS	5GM/VIAL (5GM/KIT)	N022041 001	Apr 08, 2011	Apr	DISC

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIINE

@ PHARMICS	1%	N000004 004		Jan	CAHN
------------	----	-------------	--	-----	------

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+	KV PHARM	1250MG/5ML (250MG/ML)	N021945 001	Feb 03, 2011	Feb	NEWA
---	----------	-----------------------	-------------	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP		SANDOZ	1MG/ML	A091293 001	Mar 29, 2011	Mar	NEWA
----	--	--------	--------	-------------	--------------	-----	------

ILOPERIDONE

TABLET; ORAL

FANAPT

NOVARTIS

2MG

N022192 002 May 06, 2009 Jan CAHN

4MG

N022192 003 May 06, 2009 Jan CAHN

6MG

N022192 004 May 06, 2009 Jan CAHN

8MG

N022192 005 May 06, 2009 Jan CAHN

10MG

N022192 006 May 06, 2009 Jan CAHN

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

>A>	AB	TARO	5%	A200173 001	Apr 15, 2011	Apr	NEWA
-----	----	------	----	-------------	--------------	-----	------

>A>	AB	TEVA PHARMS USA	5%	A200481 001	Apr 18, 2011	Apr	NEWA
-----	----	-----------------	----	-------------	--------------	-----	------

	AB	TOLMAR	5%	A091044 001	Feb 28, 2011	Feb	NEWA
--	----	--------	----	-------------	--------------	-----	------

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB		HETERO DRUGS LTD	25MG	A091240 001	Apr 12, 2011	Mar	NEWA
----	--	------------------	------	-------------	--------------	-----	------

AB			50MG	A091240 002	Apr 12, 2011	Mar	NEWA
----	--	--	------	-------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	+	SANDOZ	75MG	A074464 001	May 28, 1998	Jan	CTNA
----	---	--------	------	-------------	--------------	-----	------

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

+	GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454 001	Jan 14, 2011	Jan	NEWA
---	-----------------	----------------------	-------------	--------------	-----	------

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

@ HOSPIRA 41%

A074898 001 Dec 30, 1997 Feb DISC

IOPAMIDOL-200 IN PLASTIC CONTAINER

@ HOSPIRA 41%

A074636 001 Dec 30, 1997 Feb DISC

IOPAMIDOL-250

@ HOSPIRA 51%

A074898 002 Dec 30, 1997 Feb DISC

IOPAMIDOL-250 IN PLASTIC CONTAINER

@ HOSPIRA 51%

A074636 002 Dec 30, 1997 Feb DISC

IOPAMIDOL-300

@ HOSPIRA 61%

A074898 003 Dec 30, 1997 Feb DISC

IOPAMIDOL-300 IN PLASTIC CONTAINER

@ HOSPIRA 61%

A074636 003 Dec 30, 1997 Feb DISC

IOPAMIDOL-370

@ HOSPIRA 76%

A074898 004 Dec 30, 1997 Feb DISC

IOPAMIDOL-370 IN PLASTIC CONTAINER

@ HOSPIRA 76%

A074636 004 Dec 30, 1997 Feb DISC

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

>D>	@ LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135 002	Mar 20, 2005	Apr	CMFD
>A>		EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135 002	Mar 20, 2005	Apr	CMFD

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB	MIKAH PHARMA	2.5MG	A077169 001	Apr 24, 2006	Feb	CAHN
AB		5MG	A077169 002	Apr 24, 2006	Feb	CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	ACTAVIS TOTOWA	25MG	A078669 001	Apr 08, 2011	Mar	NEWA	
AB		100MG	A078669 002	Apr 08, 2011	Mar	NEWA	
AB		150MG	A078669 003	Apr 08, 2011	Mar	NEWA	
AB		200MG	A078669 004	Apr 08, 2011	Mar	NEWA	
>D>	AB	ALEMBIC LTD	25MG	A090607 001	Jan 13, 2011	Apr	CAHN
	AB		25MG	A090607 001	Jan 13, 2011	Jan	NEWA
>D>	AB		100MG	A090607 002	Jan 13, 2011	Apr	CAHN
	AB		100MG	A090607 002	Jan 13, 2011	Jan	NEWA
>D>	AB		150MG	A090607 003	Jan 13, 2011	Apr	CAHN
	AB		150MG	A090607 003	Jan 13, 2011	Jan	NEWA
>D>	AB		200MG	A090607 004	Jan 13, 2011	Apr	CAHN
	AB		200MG	A090607 004	Jan 13, 2011	Jan	NEWA
>A>	AB	ALEMBIC PHARMS LTD	25MG	A090607 001	Jan 13, 2011	Apr	CAHN
>A>	AB		100MG	A090607 002	Jan 13, 2011	Apr	CAHN
>A>	AB		150MG	A090607 003	Jan 13, 2011	Apr	CAHN
>A>	AB		200MG	A090607 004	Jan 13, 2011	Apr	CAHN
>A>	AB	HIKMA PHARMS	25MG	A078134 001	Apr 19, 2011	Apr	NEWA
>A>	AB		100MG	A078134 002	Apr 19, 2011	Apr	NEWA
>A>	AB		150MG	A078134 003	Apr 19, 2011	Apr	NEWA
>A>	AB		200MG	A078134 004	Apr 19, 2011	Apr	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	JUBILANT LIFE	5MG	A200220 001	Feb 28, 2011	Feb	NEWA
AB		25MG	A200220 002	Feb 28, 2011	Feb	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT	ALCON RES	0.005%	A091449 001	Mar 22, 2011	Mar	NEWA
AT	APOTEX	0.005%	A077697 001	Mar 22, 2011	Mar	NEWA
AT	BAUSCH AND LOMB	0.005%	A201006 001	Mar 22, 2011	Mar	NEWA
AT	MYLAN	0.005%	A201786 001	Mar 22, 2011	Mar	NEWA
AT	PHARMAFORCE	0.005%	A200925 001	Mar 22, 2011	Mar	NEWA

XALATAN

AT	+ PHARMACIA AND UPJOHN	0.005%	N020597 001	Jun 05, 1996	Mar	CFTG
----	------------------------	--------	-------------	--------------	-----	------

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

>D>	AP	GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001	Apr	DISC
>A>		@	1MG/0.2ML	A075721	001	Nov 29, 2001	Apr	DISC

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

AB		ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	Jan	NEWA
AB			500MG	A090843	002	Feb 14, 2011	Jan	NEWA
AB			750MG	A090843	003	Feb 14, 2011	Jan	NEWA
AB			1GM	A090843	004	Feb 14, 2011	Jan	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		DR REDDYS LABS LTD	5MG	A090392	001	Feb 24, 2011	Feb	NEWA
AB		GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Feb	NEWA

LEVOFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

AT		HI TECH PHARMA	0.5%	A076826	001	Feb 10, 2011	Jan	NEWA
----	--	----------------	------	---------	-----	--------------	-----	------

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

>A>	+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	Apr	NEWA
>A>	+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	Apr	NEWA

LEVONORGESTREL

TABLET; ORAL

PLAN B

@ TEVA WOMENS

AB	+		0.75MG	N021045	001	Jul 28, 1999	Feb	CAHN
			0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ VALEANT PHARM INTL

LEVORPHANOL TARTRATE

ROXANE

2MG

2MG

N008720 001 Dec 19, 1991 Mar DISC

A074278 001 Mar 31, 2000 Mar CTEC

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL

LEVO-T

AB1, AB2, AB3		ALARA PHARM	0.025MG	N021342	001	Mar 01, 2002	Feb	CTEC
AB1, AB2, AB3			0.05MG	N021342	002	Mar 01, 2002	Feb	CTEC

TABLET; ORAL

LEVO-T

AB1,	ALARA PHARM	0.075MG	N021342 003	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						
AB1,		0.088MG	N021342 004	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						
AB1,		0.1MG	N021342 005	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						
AB1,		0.112MG	N021342 006	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						
AB1,		0.125MG	N021342 007	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						
AB1,		0.137MG	N021342 012	Dec 08, 2003	Feb	CTEC
AB2,						
AB3						
AB1,		0.15MG	N021342 008	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						
AB1,		0.175MG	N021342 009	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						
AB1,		0.2MG	N021342 010	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						
AB1, +		0.3MG	N021342 011	Mar 01, 2002	Feb	CTEC
AB2,						
AB3						

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	HI TECH PHARMA	2%	A040837 001	Mar 23, 2011	Mar	NEWA
----	----------------	----	-------------	--------------	-----	------

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	GLENMARK GENERICS	450MG	A091616 001	Feb 14, 2011	Jan	NEWA
----	-------------------	-------	-------------	--------------	-----	------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

>D>	AB	ALEMBIC LTD	25MG	A090428 001	Oct 06, 2010	Apr	CAHN
>D>	AB		100MG	A090428 003	Oct 06, 2010	Apr	CAHN
>A>	AB	ALEMBIC PHARMS LTD	25MG	A090428 001	Oct 06, 2010	Apr	CAHN
>A>	AB		50MG	A090428 002	Oct 06, 2010	Apr	NEWA
>A>	AB		50MG	A090428 002	Oct 06, 2010	Apr	NEWA
>A>	AB		100MG	A090428 003	Oct 06, 2010	Apr	CAHN
	AB	MYLAN	25MG	A091590 001	Oct 06, 2010	Jan	NEWA
	AB		50MG	A091590 002	Oct 06, 2010	Jan	NEWA
	AB		100MG	A091590 003	Oct 06, 2010	Jan	NEWA

LOTEPREDNOL ETABONATE

>A>	LOINTMENT; OPHTHALMIC
-----	-----------------------

>A>	LOTEMAX
-----	---------

>A>	+	BAUSCH AND LOMB	0.5%	N200738 001	Apr 15, 2011	Apr	NEWA
-----	---	-----------------	------	-------------	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451 001	Feb 23, 2011	Feb	NEWA
AA		25MG	A201451 002	Feb 23, 2011	Feb	NEWA
AA		50MG	A201451 003	Feb 23, 2011	Feb	NEWA
AA	JUBILANT CADISTA	12.5MG	A040659 001	Jun 04, 2010	Jan	CAHN
AA		25MG	A040659 002	Jun 04, 2010	Jan	CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

AB	MYLAN	7.5MG	A077934 001	Jul 20, 2006	Feb	CAHN
AB		15MG	A077934 002	Jul 20, 2006	Feb	CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	SANDOZ	500MG/VIAL	A091201 001	Mar 29, 2011	Mar	NEWA
AP		1GM/VIAL	A091201 002	Mar 29, 2011	Mar	NEWA
	MERREM					
AP	+ ASTRAZENECA	500MG/VIAL	N050706 003	Jun 21, 1996	Mar	CTNA
AP	+	1GM/VIAL	N050706 001	Jun 21, 1996	Mar	CTNA

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MYLAN	500MG	A075973 001	Jan 25, 2002	Feb	CAHN
AB		850MG	A075973 002	Jan 25, 2002	Feb	CAHN
AB		1GM	A075973 003	Jan 25, 2002	Feb	CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB	TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842 001	Aug 29, 2005	Feb	CFTG
AB	+	850MG;EQ 15MG BASE	N021842 002	Aug 29, 2005	Feb	CFTG
	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE					
AB	MYLAN	500MG;EQ 15MG BASE	A090406 001	Feb 25, 2011	Feb	NEWA
AB		850MG;EQ 15MG BASE	A090406 002	Feb 25, 2011	Feb	NEWA

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

>D>	+ NOVARTIS	0.2MG	N006035 003		Apr	CTEC
>A>	AB +	0.2MG	N006035 003		Apr	CTEC
>A>	METHYLERGONOVINE MALEATE					
>A>	AB NOVEL LABS INC	0.2MG	A091577 001	May 02, 2011	Apr	NEWA

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB	JUBILANT CADISTA	4MG	A040189 001	Oct 31, 1997	Jan	CAHN
AB		8MG	A040189 002	Oct 31, 1997	Jan	CAHN
AB		16MG	A040189 003	Jul 20, 2007	Jan	CAHN
AB		32MG	A040189 004	Jul 20, 2007	Jan	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

>A>	AP	HEMOPARM	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Apr	CAHN
>A>	AP		EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Apr	CAHN
>D>	AP	HEMOPHARM USA	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Apr	CAHN
>D>	AP		EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Apr	CAHN
		@ HOSPIRA	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987	Feb	DISC
		@	EQ 1GM BASE/VIAL	A089174	001	Aug 18, 1987	Feb	DISC

METRONIDAZOLE

GEL; TOPICAL

METRONIDAZOLE

AB		G AND W LABS INC	0.75%	A078178	001	Jan 19, 2011	Jan	NEWA
----	--	------------------	-------	---------	-----	--------------	-----	------

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+	ASTELLAS	100MG/VIAL	N021506	003	Jun 27, 2006	Jan	CRLD
---	----------	------------	---------	-----	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDOZALAM HYDROCHLORIDE

>A>	AP	SAGENT STRIDES	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr	NEWA
>A>	AP		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr	NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

@	HOSPIRA	EQ 1MG BASE/ML	A075884	001	May 28, 2002	Feb	DISC
---	---------	----------------	---------	-----	--------------	-----	------

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB		ACTAVIS ELIZABETH	15MG	A077959	001	Feb 14, 2011	Jan	NEWA
AB			30MG	A077959	002	Feb 14, 2011	Jan	NEWA
AB			45MG	A077959	003	Feb 14, 2011	Jan	NEWA

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CDFR
---	-----------------	------------	---------	-----	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB		LUPIN LTD	500MG	A090445	001	Jan 12, 2011	Jan	NEWA
AB			750MG	A090445	002	Jan 12, 2011	Jan	NEWA

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

>A>	AP	IBI	EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Apr	NEWA
>D>	+	SANDOZ	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Apr	CTEC

INJECTABLE; INJECTION

NAFCILLIN SODIUM

>A>	AP	+	SANDOZ	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Apr	CTEC
-----	----	---	--------	-------------------	---------	-----	--------------	-----	------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB		ELITE LABS	50MG	A075274	001	May 26, 1999	Feb	CAHN
----	--	------------	------	---------	-----	--------------	-----	------

NAPROXEN

TABLET; ORAL

NAPROXEN

AB		MARKSANS PHARMA	250MG	A091416	001	Feb 14, 2011	Jan	NEWA
AB			375MG	A091416	002	Feb 14, 2011	Jan	NEWA
AB			500MG	A091416	003	Feb 14, 2011	Jan	NEWA

NARATRIPTAN

TABLET; ORAL

NARATRIPTAN

>A>	AB		APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Apr	NEWA
>A>	AB			EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Apr	NEWA
	AB		SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB		INDICUS PHARMA	EQ 1MG BASE	A200502	001	Feb 28, 2011	Feb	NEWA
AB			EQ 2.5MG BASE	A200502	002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

AB		WATSON LABS	60MG	A077462	001	Mar 30, 2011	Mar	NEWA
AB			120MG	A077462	002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

VIRAMUNE XR

	+	BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar	NEWA
--	---	----------------------	-------	---------	-----	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

>D>	AB1		BIOVAIL	30MG	A075269	001	Dec 04, 2000	Apr	CAHN
>D>	AB2			30MG	A075289	002	Feb 06, 2001	Apr	CAHN
>D>	AB2			60MG	A075289	001	Sep 27, 2000	Apr	CAHN
>D>	AB1			60MG	A075269	002	Dec 04, 2000	Apr	CAHN
>D>	AB1			90MG	A076070	001	Aug 16, 2002	Apr	CAHN
>A>	AB1		VALEANT INTL	30MG	A075269	001	Dec 04, 2000	Apr	CAHN
>A>	AB2			30MG	A075289	002	Feb 06, 2001	Apr	CAHN
>A>	AB2			60MG	A075289	001	Sep 27, 2000	Apr	CAHN
>A>	AB1			60MG	A075269	002	Dec 04, 2000	Apr	CAHN
>A>	AB1			90MG	A076070	001	Aug 16, 2002	Apr	CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB	MYLAN	8.5MG	A091001 001	Jan 26, 2011	Jan	NEWA
AB		17MG	A091001 002	Jan 26, 2011	Jan	NEWA
AB		25.5MG	A091001 003	Jan 26, 2011	Jan	NEWA
AB		34MG	A091001 004	Jan 26, 2011	Jan	NEWA
SULAR						
AB	+ SHIONOGI PHARMA	8.5MG	N020356 008	Jan 02, 2008	Jan	CFTG
AB	+	17MG	N020356 007	Jan 02, 2008	Jan	CFTG
AB		25.5MG	N020356 006	Jan 02, 2008	Jan	CFTG
AB	+	34MG	N020356 005	Jan 02, 2008	Jan	CFTG

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

>A>	AB	+ SHIONOGI INC	25MG/5ML	N009175 001		Apr	CFTG
>D>		+ SHIONOGI PHARMA	25MG/5ML	N009175 001		Apr	CFTG
>A>		NITROFURANTOIN					
>A>	AB	AMNEAL PHARMS	25MG/5ML	A201679 001	May 11, 2011	Apr	NEWA

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB	MYLAN	150MG	A075934 001	Jul 09, 2002	Feb	CAHN
AB		300MG	A075934 002	Jul 09, 2002	Feb	CAHN

NYSTATIN

SUSPENSION; ORAL

NYSTATIN

AA	VISTAPHARM	100,000 UNITS/ML	A065422 001	Mar 07, 2011	Feb	NEWA
----	------------	------------------	-------------	--------------	-----	------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

>A>	AP	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986 001	May 11, 2011	Apr	NEWA
>A>	AP		EQ 1MG BASE/ML	A090986 002	May 11, 2011	Apr	NEWA
OCTREOTIDE ACETATE (PRESERVATIVE FREE)							
	AP	BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198 001	Feb 10, 2011	Jan	NEWA
	AP		EQ 0.1MG BASE/ML	A079198 002	Feb 10, 2011	Jan	NEWA
	AP		EQ 0.5MG BASE/ML	A079198 003	Feb 10, 2011	Jan	NEWA
>A>	AP	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985 001	May 11, 2011	Apr	NEWA
>A>	AP		EQ 0.1MG BASE/ML	A090985 002	May 11, 2011	Apr	NEWA
>A>	AP		EQ 0.5MG BASE/ML	A090985 003	May 11, 2011	Apr	NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

AB	RANBAXY	4MG	A078602 001	Feb 24, 2011	Feb	NEWA
AB		8MG	A078602 002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	TEVA	EQ 2MG BASE/ML	A076876 001	Nov 22, 2006	Jan	CMFD
----	------	----------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

>D>	AP	HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Apr	CRLD
>A>	AP	+	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Apr	CRLD

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483	001	Jan 31, 2011	Jan	NEWA
AA	SILARX	EQ 4MG BASE/5ML	A091342	001	Jan 27, 2011	Jan	NEWA

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

AB	TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011	Mar	NEWA
AB		EQ 8MG BASE	A077729	002	Mar 28, 2011	Mar	NEWA
AB		EQ 24MG BASE	A077729	003	Mar 28, 2011	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Jan	NEWA
>A>	AP	50MG/VIAL	A090849	001	Apr 28, 2011	Apr	NEWA
>A>	AP	100MG/VIAL	A090849	002	Apr 28, 2011	Apr	NEWA
AP		100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Jan	NEWA

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB	MYLAN	600MG	A075847	001	Feb 28, 2001	Feb	CAHN
----	-------	-------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB	COASTAL PHARMS	5MG	A091313	001	Feb 18, 2011	Feb	NEWA
AB		15MG	A091313	002	Feb 18, 2011	Feb	NEWA
AB		30MG	A091313	003	Feb 18, 2011	Feb	NEWA
AB	RHODES PHARMS	5MG	A091490	001	Mar 09, 2011	Feb	NEWA
AB		10MG	A091490	002	Mar 09, 2011	Feb	NEWA
AB		15MG	A091490	003	Mar 09, 2011	Feb	NEWA
AB		20MG	A091490	004	Mar 09, 2011	Feb	NEWA
AB		30MG	A091490	005	Mar 09, 2011	Feb	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	TEVA	5MG	A091443	002	Feb 15, 2011	Jan	NEWA
AB		10MG	A091443	001	Feb 15, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@	ENDO PHARMS	7.5MG	N021610	005	Feb 29, 2008	Feb	DISC
@		15MG	N021610	006	Feb 29, 2008	Feb	DISC

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Jan	NEWA
AB	DR REDDYS LABS LTD	EQ 20MG BASE	A077619	001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A077619	002	Jan 19, 2011	Jan	NEWA

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	KUDCO IRELAND	EQ 20MG BASE	A078281 001	Jan 20, 2011	Jan	NEWA
AB		EQ 40MG BASE	A078281 002	Jan 20, 2011	Jan	NEWA
AB	MATRIX LABS LTD	EQ 20MG BASE	A090970 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090970 002	Jan 19, 2011	Jan	NEWA
AB	TORRENT PHARMS	EQ 20MG BASE	A090074 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090074 002	Jan 19, 2011	Jan	NEWA
AB	WOCKHARDT	EQ 20MG BASE	A091231 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A091231 002	Jan 19, 2011	Jan	NEWA

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

>A>	AB	MYLAN	EQ 37.5MG BASE	A091427 001	Apr 14, 2011	Apr	NEWA
		PAXIL CR					
>D>	+	GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936 003	Dec 06, 2000	Apr	CTEC
>A>	AB	+	EQ 37.5MG BASE	N020936 003	Dec 06, 2000	Apr	CTEC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

>D>	AB	BIOVAIL	400MG	A075028 001	Jul 20, 1998	Apr	CAHN
>A>	AB	VALEANT INTL	400MG	A075028 001	Jul 20, 1998	Apr	CAHN

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	37.5MG	A200272 001	Jan 31, 2011	Jan	NEWA
----	-----------------	--------	-------------	--------------	-----	------

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386 001	Sep 15, 2009	Jan	CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386 002	Sep 15, 2009	Jan	CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386 003	Sep 15, 2009	Jan	CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446 001	Sep 15, 2009	Jan	CAHN

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@	MYLAN	10MG	A074043 001	Sep 22, 1992	Feb	CAHN
@		20MG	A074043 002	Sep 22, 1992	Feb	CAHN

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	JUBILANT CADISTA	1MG	A040611 001	Jun 06, 2005	Jan	CAHN
AB		5MG	A040362 002	Aug 29, 2001	Jan	CAHN
AB		10MG	A040362 001	Aug 29, 2001	Jan	CAHN
AB		20MG	A040362 003	Jun 29, 2005	Jan	CAHN

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

AB	JUBILANT CADISTA	EQ 5MG BASE	A040268 001	Feb 27, 1998	Jan	CAHN
AB		EQ 10MG BASE	A040268 002	Feb 27, 1998	Jan	CAHN

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+	ROXANE	15MG	A080927 002		Jan	CMFD
---	--------	------	-------------	--	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

@	XANODYNE PHARM	65MG	N010997 003		Jan	DISC
---	----------------	------	-------------	--	-----	------

PROPOXYPHENE HYDROCHLORIDE

@	TEVA	65MG	A088615 001	Oct 22, 1984	Mar	DISC
---	------	------	-------------	--------------	-----	------

@	VINTAGE PHARMS	65MG	A040908 001	Jul 17, 2009	Mar	DISC
---	----------------	------	-------------	--------------	-----	------

@	WEST WARD	65MG	A083501 001		Jan	DISC
---	-----------	------	-------------	--	-----	------

PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVON-N

@	XANODYNE PHARM	100MG	N016862 002		Jan	DISC
---	----------------	-------	-------------	--	-----	------

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	60MG	A090321 001	Mar 25, 2011	Mar	NEWA
----	----------------------	------	-------------	--------------	-----	------

AB		80MG	A090321 002	Mar 25, 2011	Mar	NEWA
----	--	------	-------------	--------------	-----	------

AB		120MG	A090321 003	Mar 25, 2011	Mar	NEWA
----	--	-------	-------------	--------------	-----	------

AB		160MG	A090321 004	Mar 25, 2011	Mar	NEWA
----	--	-------	-------------	--------------	-----	------

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	MYLAN	60MG	A070213 005	Apr 08, 2011	Mar	NEWA
----	-------	------	-------------	--------------	-----	------

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

AB	MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005	Feb	CAHN
----	-------	-------------	-------------	--------------	-----	------

AB		EQ 10MG BASE	A076036 002	Jan 28, 2005	Feb	CAHN
----	--	--------------	-------------	--------------	-----	------

AB		EQ 20MG BASE	A076036 003	Jan 28, 2005	Feb	CAHN
----	--	--------------	-------------	--------------	-----	------

AB		EQ 40MG BASE	A076036 004	Jan 28, 2005	Feb	CAHN
----	--	--------------	-------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

@	MYLAN	EQ 150MG BASE	A075564 001	Oct 27, 2000	Feb	CAHN
---	-------	---------------	-------------	--------------	-----	------

@		EQ 300MG BASE	A075564 002	Oct 27, 2000	Feb	CAHN
---	--	---------------	-------------	--------------	-----	------

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA	HI TECH PHARMA	EQ 15MG BASE/ML	A091078 001	Mar 22, 2011	Mar	NEWA
----	----------------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 150MG BASE	A074023 001	Aug 22, 1997	Feb	CAHN
----	-------	---------------	-------------	--------------	-----	------

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 300MG BASE	A074023 002	Aug 22, 1997	Feb	CAHN
----	-------	---------------	-------------	--------------	-----	------

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+	SALIX PHARMS	550MG	N022554 001	Mar 24, 2010	Feb	CRLD
---	--------------	-------	-------------	--------------	-----	------

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

AA	TARO	1MG/ML	A090347 001	Feb 07, 2011	Jan	NEWA
----	------	--------	-------------	--------------	-----	------

TABLET; ORAL

RISPERIDONE

@	RATIOPHARM	0.25MG	A077784 001	Jun 08, 2010	Feb	DISC
---	------------	--------	-------------	--------------	-----	------

@		0.5MG	A077784 002	Jun 08, 2010	Feb	DISC
---	--	-------	-------------	--------------	-----	------

@		1MG	A077784 003	Jun 08, 2010	Feb	DISC
---	--	-----	-------------	--------------	-----	------

@		2MG	A077784 004	Jun 08, 2010	Feb	DISC
---	--	-----	-------------	--------------	-----	------

@		3MG	A077784 005	Jun 08, 2010	Feb	DISC
---	--	-----	-------------	--------------	-----	------

@		4MG	A077784 006	Jun 08, 2010	Feb	DISC
---	--	-----	-------------	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	MYLAN	0.5MG	A091537 001	Mar 30, 2011	Mar	NEWA
----	-------	-------	-------------	--------------	-----	------

AB		1MG	A091537 002	Mar 30, 2011	Mar	NEWA
----	--	-----	-------------	--------------	-----	------

AB		2MG	A091537 003	Mar 30, 2011	Mar	NEWA
----	--	-----	-------------	--------------	-----	------

AB		3MG	A091537 004	Mar 30, 2011	Mar	NEWA
----	--	-----	-------------	--------------	-----	------

AB		4MG	A091537 005	Mar 30, 2011	Mar	NEWA
----	--	-----	-------------	--------------	-----	------

>A>	AB	WATSON LABS FLORIDA	0.5MG	A076996 001	Apr 19, 2011	Apr	NEWA
-----	----	---------------------	-------	-------------	--------------	-----	------

>A>	AB		1MG	A076996 002	Apr 19, 2011	Apr	NEWA
-----	----	--	-----	-------------	--------------	-----	------

>A>	AB		2MG	A076996 003	Apr 19, 2011	Apr	NEWA
-----	----	--	-----	-------------	--------------	-----	------

>A>	AB		3MG	A076996 004	Apr 19, 2011	Apr	NEWA
-----	----	--	-----	-------------	--------------	-----	------

>A>	AB		4MG	A076996 005	Apr 19, 2011	Apr	NEWA
-----	----	--	-----	-------------	--------------	-----	------

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458 001	Jul 28, 2010	Jan	CAHN
----	----------------	--------------------	-------------	--------------	-----	------

AP		100MG/10ML (10MG/ML)	A091458 002	Jul 28, 2010	Jan	CAHN
----	--	----------------------	-------------	--------------	-----	------

ROFLUMILAST

TABLET; ORAL

DALIRESP

+	FOREST RES INST INC	500MCG	N022522 001	Feb 28, 2011	Feb	NEWA
---	---------------------	--------	-------------	--------------	-----	------

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+	EISAI INC	40MG/ML	N201367 001	Mar 03, 2011	Mar	NEWA
---	-----------	---------	-------------	--------------	-----	------

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+	MARATHON PHARMS	50MG	A086101 001	Oct 03, 1983	Jan	CAHN
---	-----------------	------	-------------	--------------	-----	------

+		100MG	A086101 002	Oct 03, 1983	Jan	CAHN
---	--	-------	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@ ROXANE	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	DISC
----------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006	Apr	DISC
>A>		@	EQ 25MG BASE	A075719	003	Jun 30, 2006	Apr	DISC
>D>	AB		EQ 50MG BASE	A075719	001	Jun 30, 2006	Apr	DISC
>A>		@	EQ 50MG BASE	A075719	001	Jun 30, 2006	Apr	DISC
>D>	AB		EQ 100MG BASE	A075719	002	Jun 30, 2006	Apr	DISC
>A>		@	EQ 100MG BASE	A075719	002	Jun 30, 2006	Apr	DISC
	AB	MYLAN	EQ 25MG BASE	A076540	001	Mar 20, 2007	Feb	CAHN
	AB		EQ 50MG BASE	A076540	002	Mar 20, 2007	Feb	CAHN
	AB		EQ 100MG BASE	A076540	003	Mar 20, 2007	Feb	CAHN
		@ ROXANE	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	DISC
		@	EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	DISC
		@	EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	DISC

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	62.5MG/5ML	N020955	001	Feb 18, 1999	Mar	CFTG
		SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE						
AB		GENERAMEDIX	62.5MG/5ML	A078215	001	Mar 31, 2011	Mar	NEWA

>D> SODIUM FLUORIDE F-18

>D> INJECTABLE; INTRAVENOUS

>D> SODIUM FLUORIDE F 18

>D>	+	NIH NCI DCTD	10-200mCi/ML	N022494	001	Jan 26, 2011	Apr	DISC
>A>		@	10-200mCi/ML	N022494	001	Jan 26, 2011	Apr	DISC
	+		10-200mCi/ML	N022494	001	Jan 26, 2011	Jan	NEWA

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5G M/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Feb	CTNA
---	-------------	--	---------	-----	--------------	-----	------

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5G M/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Jan	NEWA
---	-------------	--	---------	-----	--------------	-----	------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO PHARMS	0.9%	N022408	001	Jan 18, 2011	Jan	NEWA
---	----------------	------	---------	-----	--------------	-----	------

SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN SUCCINATE

@	ROXANE	EQ 25MG BASE	A078241	001	Aug 10, 2009	Mar	DISC
@		EQ 50MG BASE	A078241	002	Aug 10, 2009	Mar	DISC
@		EQ 100MG BASE	A078241	003	Aug 10, 2009	Mar	DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	JUBILANT CADISTA	EQ 1MG BASE	A075317 001	Dec 20, 2004	Jan	CAHN
AB		EQ 2MG BASE	A075317 002	Dec 20, 2004	Jan	CAHN
AB		EQ 5MG BASE	A075317 003	Dec 20, 2004	Jan	CAHN
AB		EQ 10MG BASE	A075317 004	Dec 20, 2004	Jan	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

AB	MYLAN	EQ 250MG BASE	A077136 001	Jul 02, 2007	Feb	CAHN
	@ ROXANE	EQ 250MG BASE	A077223 001	Jul 02, 2007	Feb	DISC

TERBUTALINE SULFATE

TABLET; ORAL

TERBUTALINE SULFATE

AB	+ IMPAX LABS	5MG	A075877 002	Jun 26, 2001	Jan	CRLD
----	--------------	-----	-------------	--------------	-----	------

TESTOSTERONE

>A> GEL, METERED; TRANSDERMAL

>A> ANDROGEL

>A>	+ ABBOTT PRODS	1.62% (20.25MG/1.25GM ACTIVATION)	N022309 001	Apr 29, 2011	Apr	NEWA
-----	----------------	-----------------------------------	-------------	--------------	-----	------

FORTESTA

	+ ENDO PHARMS	10MG/0.5GM ACTIVATION	N021463 001	Dec 29, 2010	Mar	CPOT
--	---------------	-----------------------	-------------	--------------	-----	------

THEOPHYLLINE

SOLUTION; ORAL

THEOPHYLLINE

	+ SILARX	80MG/15ML	A091156 001	Apr 13, 2011	Mar	NEWA
--	----------	-----------	-------------	--------------	-----	------

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

AB	MYLAN	250MG	A075161 001	Sep 13, 1999	Feb	CAHN
----	-------	-------	-------------	--------------	-----	------

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT	FERA PHARMS	0.3%	A065026 001	Sep 11, 2001	Mar	CAHN
----	-------------	------	-------------	--------------	-----	------

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191 001	Mar 09, 2011	Feb	NEWA
AP	SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284 001	Jan 26, 2011	Jan	NEWA

SOLUTION; INTRAVENOUS

TOPOTECAN

AP	HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582 001	Feb 02, 2011	Feb	NEWA
	SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199 001	Feb 25, 2011	Feb	NEWA
		EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199 002	Feb 25, 2011	Feb	NEWA
AP	+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199 003	Feb 25, 2011	Feb	NEWA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB	VINTAGE PHARMS	5MG	A090613 001	Mar 22, 2011	Mar	NEWA
AB		10MG	A090613 002	Mar 22, 2011	Mar	NEWA
AB		20MG	A090613 003	Mar 22, 2011	Mar	NEWA
AB		100MG	A090613 004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	50MG	A090404 001	Jan 31, 2011	Jan	NEWA
----	----------------------	------	-------------	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP	PHARMAFORCE	100MG/ML	A091330 001	Mar 08, 2011	Feb	NEWA
----	-------------	----------	-------------	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP	PHARMAFORCE	100MG/ML	A091329 001	Mar 08, 2011	Feb	NEWA
----	-------------	----------	-------------	--------------	-----	------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361 001	Aug 02, 2006	Feb	CAHN
AB		EQ 50MG BASE	A077361 002	Aug 02, 2006	Feb	CAHN
AB		EQ 100MG BASE	A077361 003	Aug 02, 2006	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370 001	Mar 16, 2011	Feb	NEWA
AB		EQ 1GM BASE	A090370 002	Mar 16, 2011	Feb	NEWA

>A> VANDETANIB

>A> TABLET; ORAL

>A> VANDETANIB

>A>	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Apr	NEWA
>A>	+	300MG	N022405 002	Apr 06, 2011	Apr	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834 001	Apr 14, 2011	Apr	NEWA
>A>	AB		EQ 75MG BASE	A200834 002	Apr 14, 2011	Apr	NEWA
>A>	AB		EQ 150MG BASE	A200834 003	Apr 14, 2011	Apr	NEWA
>A>	AB	BIOVAIL LABS INTL	EQ 75MG BASE	A090071 002	Apr 15, 2011	Apr	NEWA
>A>	AB		EQ 150MG BASE	A090071 003	Apr 15, 2011	Apr	NEWA
>A>	AB	DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421 001	May 06, 2011	Apr	NEWA
>A>	AB		EQ 75MG BASE	A078421 002	May 06, 2011	Apr	NEWA
>A>	AB		EQ 150MG BASE	A078421 003	May 06, 2011	Apr	NEWA
>A>	AB	WOCKHARDT	EQ 37.5MG BASE	A078865 001	Apr 14, 2011	Apr	NEWA
>A>	AB		EQ 75MG BASE	A078865 002	Apr 14, 2011	Apr	NEWA
>A>	AB		EQ 150MG BASE	A078865 003	Apr 14, 2011	Apr	NEWA
>A>	AB	ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174 001	Apr 14, 2011	Apr	NEWA
>A>	AB		EQ 75MG BASE	A090174 002	Apr 14, 2011	Apr	NEWA

CAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

>A>	AB	ZYDUS PHARMS USA INC	EQ 150MG BASE	A090174	003	Apr 14, 2011	Apr	NEWA
-----	----	----------------------	---------------	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VILIBRYD

TROVIS PHARMS

10MG

N022567 001 Jan 21, 2011 Jan NEWA

20MG

N022567 002 Jan 21, 2011 Jan NEWA

+

40MG

N022567 003 Jan 21, 2011 Jan NEWA

VINCRIStINE SULFATE

INJECTABLE; INJECTION

VINCRIStINE SULFATE

@ APP PHARMS

1MG/ML

A076401 001 Oct 28, 2003 Jan DISC

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

AP

LUITPOLD

10MG/ML

A091457 001 May 06, 2010 Feb CAHN

TABLET; ORAL

ZIDOVUDINE

@ MATRIX LABS LTD

100MG

N200732 001 Feb 23, 2011 Feb NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB

MYLAN

5MG

A078016 001 Apr 23, 2007 Feb CAHN

AB

10MG

A078016 002 Apr 23, 2007 Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

>A>

AB

ANCHEN PHARMS

6.25MG

A078148 002 Apr 14, 2011 Apr NEWA

>A>

AB

SYNTHON PHARMS

6.25MG

A078483 001 Apr 12, 2011 Apr NEWA

OTC DRUG PRODUCT LIST - 31ST EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

2-1

CETIRIZINE HYDROCHLORIDE

SOLUTION; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>A>	SILARX	5MG/5ML	A091130	001	Apr 22, 2011	Apr	NEWA
-----	--------	---------	---------	-----	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>A>	SILARX	5MG/5ML	A091130	002	Apr 22, 2011	Apr	NEWA
-----	--------	---------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

>A>	+ CARDINAL HLTH	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN
-----	-----------------	-----------------	---------	-----	--------------	-----	------

>D>	+ CAREFUSION	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN
-----	--------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

>A>	+ CARDINAL HLTH	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN
-----	-----------------	-----------------	---------	-----	--------------	-----	------

>D>	+ CAREFUSION	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN
-----	--------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

>A>	+ CARDINAL HLTH	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Apr	NEWA
-----	-----------------	-----------------	---------	-----	--------------	-----	------

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

MYLAN	10MG	A075674	001	Dec 21, 2001	Feb	CAHN
-------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Jan	NEWA
---	-------------------	----------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+	SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jan	NEWA
---	-------------------	----------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+	SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jan	NEWA
---	-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+	SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jan	NEWA
---	-------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

+	180MG	N020872	010	Jan 24, 2011	Jan	NEWA
---	-------	---------	-----	--------------	-----	------

ALLEGRA HIVES

SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

+	180MG	N020872	009	Jan 24, 2011	Jan	NEWA
---	-------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

TEVA	30MG	A076447	004	Apr 13, 2011	Mar	NEWA
------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

TEVA	30MG	A076447	005	Apr 13, 2011	Mar	NEWA
------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	180MG	A076502 008	Apr 12, 2011	Mar	NEWA
TEVA	60MG	A076447 006	Apr 13, 2011	Mar	NEWA
	180MG	A076447 008	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502 007	Apr 12, 2011	Mar	NEWA
	180MG	A076502 009	Apr 12, 2011	Mar	NEWA
TEVA	60MG	A076447 007	Apr 13, 2011	Mar	NEWA
	180MG	A076447 009	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	60MG;120MG	N020786 002	Jan 24, 2011	Jan	NEWA
---	-------------------	------------	-------------	--------------	-----	------

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+	SANOFI AVENTIS US	180MG;240MG	N021704 002	Jan 24, 2011	Jan	NEWA
---	-------------------	-------------	-------------	--------------	-----	------

IBUPROFEN

TABLET; ORAL

IBUPROFEN

MARKSANS PHARMA	200MG	A091237 001	Feb 08, 2011	Jan	NEWA
	200MG	A091239 001	Feb 01, 2011	Jan	NEWA
MERRO PHARM	200MG	A070985 001	Oct 02, 1987	Jan	CAHN
SVADS HOLDINGS SA	200MG	A079129 001	Mar 28, 2011	Mar	NEWA
	200MG	A091355 001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

NOVOLIN N

+	NOVO NORDISK INC	100 UNITS/ML	N019959 001	Jul 01, 1991	Jan	CRLD
---	------------------	--------------	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

PLAN B

+	TEVA WOMENS	0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN
---	-------------	--------	-------------	--------------	-----	------

MINOXIDIL

AEROSOL, FOAM; TOPICAL

>A>	MINOXIDIL					
>A>	PERRIGO ISRAEL	5%	A091344 001	Apr 28, 2011	Apr	NEWA

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

MARKSANS PHARMA	EQ 200MG BASE	A090545 001	Mar 16, 2011	Feb	NEWA
-----------------	---------------	-------------	--------------	-----	------

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

>A>	ANBEX	65MG	N018664 002	May 12, 2011	Apr	NEWA
-----	-------	------	-------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

	MYLAN	EQ 75MG BASE	A075497 001	Jan 14, 2000	Feb	CAHN
>A>	PERRIGO R AND D	EQ 150MG BASE	A091429 002	May 11, 2011	Apr	NEWA
>A>		EQ 150MG BASE	A091429 001	May 11, 2011	Apr	NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 4 APRIL 2011

NO APRIL 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N202379	001				>A> NCE	Apr 28, 2016
<u>ADAPALENE - DIFFERIN</u>						
N021753	001	7868044	Mar 12, 2023	U-1078		
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545	001				NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545	002				NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545	003				NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545	004				NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045	001	5559111	Jul 21, 2018	DS DP U-3	NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045	002	5559111	Jul 21, 2018	DS DP U-3	NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045	003	5559111	Jul 21, 2018	DS DP U-3	NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045	004	5559111	Jul 21, 2018	DS DP U-3	NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045	005	5559111	Jul 21, 2018	DS DP U-3	NCE	Mar 05, 2012
<u>ALVIMOPAN - ENTEREG</u>						
N021775	001	5250542	Mar 29, 2016	DS DP U-878		
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381	005				PC	Jul 02, 2011
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381	006				PC	Jul 02, 2011
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303	001	RE42096	Oct 21, 2018	DP		
		RE42096*PED	Apr 21, 2019			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303	006	RE42096	Oct 21, 2018	DP		
		RE42096*PED	Apr 21, 2019			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303	002	RE42096	Oct 21, 2018	DP		
		RE42096*PED	Apr 21, 2019			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303	004	RE42096	Oct 21, 2018	DP		
		RE42096*PED	Apr 21, 2019			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 001					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 002					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 003					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 004					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 005					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021436 006					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021713 001					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 002					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021729 003					I-633	Feb 16, 2014
<u>ARIPIRAZOLE - ABILIFY</u>						
N021866 001					I-633	Feb 16, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 001					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 002					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 003					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 004					D-130	Feb 04, 2014
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZITHROMYCIN - ZMAX</u>						
N050797 001	7887844	Feb 14, 2024	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	7897646	Sep 09, 2018	U-1118			
<u>CELECOXIB - CELEBREX</u>						
N020998 001	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 002	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 003	5760068	Jun 02, 2015	U-672			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N021441 001	>A> 7863287	Feb 28, 2027	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 001					I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 002					I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 003					I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 001	4847265	Nov 17, 2011	DS DP			
	4847265*PED	May 17, 2012				
	5576328	Jan 31, 2014	U-432	Y		
	5576328*PED	Jul 31, 2014				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 002	4847265	Nov 17, 2011	DS DP			
	4847265*PED	May 17, 2012				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
<u>DESIRUDIN RECOMBINANT - IPRIVASK</u>						
N021271 001	6103515	Aug 15, 2017	DS			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	7884095	Feb 24, 2029	U-1111			
	7884095*PED	Aug 24, 2029				
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N021005 001	>A> 5929048	Jun 17, 2014	U-402			
	>A> 5985850	Aug 11, 2015	DP			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	6133251	Oct 25, 2016	DP U-828	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-1	Y		
	6884793	Oct 25, 2016	DP	Y		
<u>DORIPENEM - DORIBAX</u>						
N022106 001	5317016	Jun 05, 2015	DS DP U-282			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	5317016	Jun 05, 2015	DS DP U-282			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	7915307	Aug 24, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	7915307	Aug 24, 2027	U-620			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	>A> 7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	>A> 7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	>A> 7547719	Jul 13, 2025	DS DP U-930			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 001	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 002	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N022262 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N022573 001	5552394	Jul 22, 2014	U-828			
	6667050	Apr 06, 2019	DP U-828			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	7887845	Mar 25, 2019	DP			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
	7037917	Nov 05, 2019	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001					ODE	Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002					ODE	Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003					NCE ODE	Mar 30, 2014 Oct 29, 2017
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-98	Jan 31, 2014
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519 001					>A> NC	Apr 23, 2014
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 001	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 003	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 001	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 002	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	>A> 7862832	Jun 15, 2028	DP			
	>A> 7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	>A> 7862832	Jun 15, 2028	DP			
	>A> 7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	>A> 7862832	Jun 15, 2028	DP			
	>A> 7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	>A> 7862832	Jun 15, 2028	DP			
	>A> 7862833	Jun 15, 2028	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N022180 001	7871597	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	7855230	May 11, 2019	U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	7855230	May 11, 2019	U-913			
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE</u>						
A079043 001					PC	Jul 27, 2011
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	7915243	Mar 22, 2026	DP			
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			PED	Mar 09, 2014
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				
<u>GABAPENTIN - GABAPENTIN</u>						
A078974 001					PC	Aug 22, 2011
<u>GABAPENTIN - GRALISE</u>						
N022544 001	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN - GRALISE</u>						
N022544 002	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	>A> 6818787	Nov 06, 2022	DS DP		>A> NCE	Apr 06, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 001	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 002	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 003	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 004	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 005	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE</u>						
A079183 001					PC	May 14, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 001					PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 002					PC	Jul 24, 2011
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 001					>A> M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 002					>A> M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 003					>A> M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 004					>A> M-102	Apr 29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037	001				I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037	002				I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037	003				I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037	004				I-635	Feb 25, 2014
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N022041	001	>A> 5834448	Nov 14, 2016	DP	>A> ODE	Dec 15, 2013
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N021945	001				ODE	Feb 03, 2018
<u>IMIQUIMOD - ZYCLARA</u>						
N022483	001				I-636	Mar 24, 2014
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081	001	>A> 7918833	Sep 23, 2027	DP		
		>A> 7918833*PED	Mar 23, 2028			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629	003	>A> 7918833	Sep 23, 2027	DP		
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R</u>						
N018780	001				NR	Mar 25, 2014
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R PEN</u>						
N018780	005				NR	Mar 25, 2014
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454	001				NCE	Jan 14, 2016
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065	001	6670384	Jan 23, 2022	DP U-960	NCE	Oct 16, 2012
		6670384	Jan 23, 2022	DP U-959	PED	Apr 16, 2013
		6670384*PED	Jul 23, 2022			
		7022330	Jan 23, 2022	DP U-958		
		7022330*PED	Jul 23, 2022			
		7125899	May 26, 2018	DS DP U-957		
		7125899*PED	Nov 26, 2018			
		7312237	Aug 21, 2024	U-965		
		7312237*PED	Feb 21, 2025			
		RE41393	Feb 08, 2022	U-961		
		RE41393*PED	Aug 08, 2022			
		RE41911	May 26, 2018	DS DP U-961		
		RE41911*PED	Nov 26, 2018			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 001	>A> 7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 002	>A> 7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 003	>A> 7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 004	>A> 7919115	Jan 04, 2029	DS DP			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	7855217	Nov 24, 2024	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	7855217	Nov 24, 2024	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	7855217	Nov 24, 2024	DS DP			
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 002	>A> 6500829	Dec 31, 2019	DS DP		>A> ODE	Mar 07, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 003	>A> 6500829	Dec 31, 2019	DS DP		>A> ODE	Mar 07, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N200738	001				>A> NDF >A> PED	Apr 15, 2014 Oct 15, 2014
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574	001	7919116	Mar 20, 2018	DP		
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574	002	7919116	Mar 20, 2018	DP		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024	001	>A> 7919116	Mar 20, 2018	U-973		
		>A> 7919116	Mar 20, 2018	U-1120		
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024	002	>A> 7919116	Mar 20, 2018	U-973		
		>A> 7919116	Mar 20, 2018	U-1120		
<u>METRONIDAZOLE - VANDAZOLE</u>						
N021806	001	7456207	Sep 22, 2024	DP		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256	001	7888342	Nov 05, 2021	U-882		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256	002	7888342	Nov 05, 2021	U-882		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256	003	7888342	Nov 05, 2021	U-882		
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256	004	7888342	Nov 05, 2021	U-882		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808	001	7919483	Feb 28, 2027	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808	002	7919483	Feb 28, 2027	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808	003	7919483	Feb 28, 2027	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808	004	7919483	Feb 28, 2027	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808	005	7919483	Feb 28, 2027	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808	006	7919483	Feb 28, 2027	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808	007	7919483	Feb 28, 2027	U-1078		
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808	008	7919483	Feb 28, 2027	U-1078		
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762	001				M-99	Jan 19, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N022428 001	>A> 7671070*PED	Mar 29, 2020				
<u>MUPIROCIIN CALCIUM - BACTROBAN</u>						
N050746 001	>A> 6025389	Oct 20, 2014	DP U-1122			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001	5366972	Nov 22, 2011	DS DP U-167		NDF	Mar 25, 2014
	5366972*PED	May 22, 2012				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 003	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001	5763483	Dec 27, 2016	DS U-376			
	5763483	Dec 27, 2016	DS U-1113			
	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	>A> 7923536	Dec 09, 2023	U-1117			
	RE41884	Aug 14, 2016	U-1117			
<u>PALIPERIDONE - INVEGA</u>						
N021999 001					>A> NPP	Apr 06, 2014
					>A> PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 002					>A> NPP	Apr 06, 2014
					>A> PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 003					>A> NPP	Apr 06, 2014
					>A> PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 004					>A> NPP	Apr 06, 2014
					>A> PED	Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 006					>A> NPP	Apr 06, 2014
					>A> PED	Oct 06, 2014
<u>PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE</u>						
A091427 001					>A> PC	Nov 01, 2011
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001					M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002					M-61 PED	Mar 17, 2014 Sep 17, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERFLUTREN - DEFINITY</u>						
N021064 001	5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	>A> 7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	>A> 7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	>A> 7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	>A> 7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	>A> 7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	>A> 7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	>A> 7915229	Apr 14, 2023	DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2013	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001	7169780	Oct 03, 2023	DS DP			
<u>RANOLAZINE - RANEXA</u>						
N021526 001	6369062	May 27, 2019	DP	Y		
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	>A> 7928115	Jul 24, 2029	U-1121			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Feb 11, 2014		Y		
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Feb 11, 2014		Y		
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Feb 11, 2014	U-240	Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Feb 11, 2014	U-240	Y		
<u>ROFLUMILAST - DALIRESP</u>						
N022522 001	5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	>A> 6699498	Nov 27, 2020	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	>A> 6699498	Nov 27, 2020	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	>A> 6699498	Nov 27, 2020	DP			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Aug 17, 2020	DS DP		NCE ODE	Nov 14, 2013 Nov 14, 2015
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N201444 001					ODE	Jan 14, 2018
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	7668730	Jun 16, 2024	U-1110			
	7895059	Dec 17, 2022	U-1110			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N021923 001	7897623	Jan 12, 2020	DP			
<u>SPINOSAD - NATROBA</u>						
N022408 001	5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
	6063771	Jun 22, 2019	DP U-1105			
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	7776007	Apr 09, 2025	DP			
	7901385	Jul 31, 2026	DP			
<u>TELIVUDINE - TYZEKA</u>						
N022011 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 001					>A> NP	Apr 29, 2014
<u>TESTOSTERONE - FORTESTA</u>						
N021463 001	>A> 6319913	Nov 09, 2018	U-490			
	>A> 6579865	Nov 09, 2018	DP			
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	7879828	Feb 05, 2029	DP			
<u>VANDETANIB - VANDETANIB</u>						
N022405 001	>A> 6414148	Sep 23, 2017	DS		>A> NCE	Apr 06, 2016
	>A> 7173038	Aug 14, 2021	DS DP		>A> ODE	Apr 06, 2018
<u>VANDETANIB - VANDETANIB</u>						
N022405 002	>A> 6414148	Sep 23, 2017	DS		>A> NCE	Apr 06, 2016
	>A> 7173038	Aug 14, 2021	DS DP		>A> ODE	Apr 06, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A078148 001					PC	Jun 04, 2011

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>